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Synthesis of novel ligands for the stabilization of organometallic 
complexes having potential antitumor activity 
 The design of new metal complexes as anticancer agents has received 
considerable interest in recent years. Complexes of titanium (e.g.: titanocene 
dichloride), lanthanides complexes (e.g.: texaphyrrins lanthanide) and carbenic 
complexes of gold, silver and copper showed significant biological activity, 
and have progressed into clinical trials.
 
 
Thus, the target of this PhD project are the synthesis of new ligands and metal 
complexes. Firstly 5 cyclopentadienyl pro-ligands were synthesised: 6-
phenylfulvene, 6-(p-metoxyphenyl)-fulvene e 6-(3',4'-dymethoxyphenyl)fulvene, 
6-(3',5')-dymethoxyphenyl)fulvene and 6-(2',4')-dymethoxyphenyl)fulvene. 
Then, the synthesis of 12 novel scandium, yttrium and neodymium complexes 
with these cyclopentadienyl ligands was carried out.  
The complexes were tested on DU146 (Prostatic carcinoma) and 
MDA.MB213 (Breast cancer) to verify inhibition of cell-proliferation, using 
MTT test with standard procedures. All the complex showed a strong 
concentration-dependent ability of inhibiting the growth tumor cell, referring 
to antiblastic activity. 
In the last years the synthesis of new carbenic ligands (N-methyl-N’-[2-
hydroxycyclopentan]-4,5-dychloroimydazole iodide, N-methyl-N’-[2-
hydroxycyclopentan]-4,5-dyphenylimydazole iodide, N-methyl-N’-[(2-
hydroxy-2-phenyl)ethyl]-imydazole iodide) and 8 new complexes of gold, 
silver and copper was carried out. 
The complexes were tested on MCF-7 (human mammary carcinoma 
expressing the estrogen receptor ERα/ER-positive), MDA-MB-231 (human 
mammary carcinoma not expressing the estrogen receptor/ER-negative), 
MCF-10 (breast glandular epithelium), using MTT test with standard 
 
procedures. All the molecules showed a good inhibitory effect on the 
proliferation of two cancer cell lines. Many of them did not showed na any 
inhibitory effect on healthy cell. Instead, some  compounds showed a only a 
mild effects only at very high concentrations.  
Then, it was investigated if the antiproliferative activity of the complex AuL20 
on MCF-7 was connected to the mechanisms of regulation of the cell cycle. 
Therefore, it was evaluated the level of expression of two proteins involved in 
the regulation of the cell cycle, p53 and p21 with immunoblotting, using β-
actina as “loading control”. Results showed a marked modulation of the 
expression of p21 and p53, confirming that AuL20 can stop cell proliferation 


























Biomedical inorganic chemistry has been increasingly developed in 
recent years becoming an important area of chemistry. The term 
“bioinorganic” includes a semantic contradiction that it seems to reflect a 
misconception going back to the beginning of modern science. 
In 19th century chemistry was still divided into two groups: organic 
and inorganic chemistry. “Organic” chemistry included only substances 
isolated from organisms, while “inorganic” chemistry was referred to dead 
matter. In 1828 this distinction between inorganic and organic chemistry 
became meaningless when Friedrich Wöhler discovered the conversion of 
ammonium cyanate into urea. 
(1)
 
Nowadays organic chemistry is the chemistry of hydrocarbons and 
their derivatives. It consists of non-metallic hetero-elements such as N, O and 
S. “Biochemistry” becomes the new term to designate the chemistry of living 
organisms, independent from the origin of matter. For a long time 
biochemistry was concerned mainly with organic compounds. The 
improvement of trace analytical methods has also demonstrated the 
importance of some inorganic elements in biochemical processes and it has 
revealed a multitude of partially inorganic natural products such as: 
 Metalloenzymes (ca.40% of the known enzyme), especially 
oxidoreductase (Fe, Cu, Mn, Mo, Ni, V) and hydrolase (e.g. 
phosphatases: Zn, Mg, Ca, Fe). 
 Non enzymatic metalloproteins (e.g. hemoglobin: Fe) 
 Low-molecular-weight natural products (e.g. chlorophyll: Mg) 
 Coenzymes,( vitamin B12: Co) 
 Nucleic acids: (e.g. DNA n-(M+)n M= Na, K) 
 Hormones (e.g thyroxine, triiodothyonine: I) 




 Antibiotics (e.g. ionophores: valinomycin/K) 
 Biominerals (e.g. bones, teeth, shells, coral, pearls: Ca. Si) 
After the 1960 “bioinorganic” chemistry became an independent and 
highly interdisciplinary research area. This has been possible thanks to 
scientific contributions such as: the detection and characterization techniques 
in physics; the material and specific modifications based on site-directed 
mutagenesis from the biology; in the agricultural and nutritional sciences the 
effects of inorganic elements and their mutual interdependence; in 
pharmacology it comes from the interaction between drugs and endogenous or 
exogenous inorganic substances; from medicine the imaging and other 
diagnostic aids and chemotherapy; from the toxicology and environmental 




Figure 1.1. Application of bioinorganic chemistry. 
 
The Bioinorganic Chemistry can be apply in many scientific fields such as: 
 Industrial sector 




 Anaerobic bacterial degradation in sewage plants or in sediments: Fe, 
Ni, Co; 
 Biomining (bacterial leaching, ≈15% of the global copper production): 
Cu, Au, Fe, U. 
 Environmental sector: agricultural trace elements problems (nitrogen 
fixation: Fe, Mo, V), pollution through metal species (Pb, Cd, Hg, As, 
Al, Cr), detoxification (e.g peroxidases(Fe, Mn, V) 
 Biomedical sector: radiodiagnostics (single, SPECT, PET; 
radiotherapy, Tc, I, Ga, In, Re), (MRI, x-ray, Gd, Ba, I), chemioterapy 
(Pt, Au, Li, B, Bi, As), biominerals, “inorganic” nutrients and noxious 
food components, drug development. 
 
The previous list could be expanded, but certainly the more innovative 
field of the “bioinorganic” chemistry is biomedicine. All diagnostic radiology 
analyses such as SPECT (Single Proton Emition Computed Tomography), 
PET (Positron Emission Tomography) and other imaging techniques such as 
MRI (Magnetic Resonance Imaging), x-ray, use inorganic ions. For example 
Gd(III) complexes can be safely inject as contrast agents in MRI. In fact 
contrast agents toxicity can be easily controlled by their ligand design because 
paramagnetic ions can be targeted to specific organs. Other contrast agent used 
in in radiotherapy are also Tc, I, Ga, In, Re.  
In the chemotherapy medicinal inorganic chemistry offers the possibility 
to discover novel drugs with new mechanisms of action. After the success of 
cisplatin scientists have tried to synthesize new orally administrable metal 








1.1 MRI Contrast Agents 
 
Nowadays a new powerful analysis in clinical diagnosis is MRI 
(Magnetic resonance imaging).
(3)
 Diseases can be detected from differences in 
1
H NMR resonances (mainly of H2O) between normal and abnormal tissues by 
administration of contrast agents. These molecules are generally external 
paramagnetic agents. In fact, metal ions can also characterize according to 
their behaviour in a magnetic field based on atomic number, mass, isotopic 
abundance and oxidation state. Instead the radioactive elements can be differ 
by their half-life and energy of isotopic decay. 
Most contrast agents contain Gd(III), Mn(II), or Fe(III) ions which 
have a large number of unpaired electrons (7, 5, and 5, respectively, high spin) 
and long electron spin relaxation times.
(4,5)
 
Gadolinium, for example, is a mid-series lanthanide widely used in MRI 
contrast agents.
(6)
 The electronic properties of Gd(III) is useful to enhance the 
clarity of MRI scans. 
Generally non-physiological metals, such as the lanthanides, gallium, 
indium, technetium, and many others, hydrolyse, accumulate in tissues or are 
excreted too rapidly to be used in imaging in the absence of an appropriate 
ligand. A ligand is required not only to obviate accumulation of these metals 
but also to ensure a reasonable plasma half-life and enough time to obtain a 
high-contrast image. Gadolinium needs to be used with a ligand that has high 
thermodynamic stability and one vacant coordination position to bind the 
water molecule needed for MRI. The protein-binding moiety is chosen to 
target the chelated metal ion to the right tissue.
(7)
 
Several Gd(III) complexes are now approved for clinical use and 
applied for the detection of abnormalities of the blood-brain barrier.(8) 
 




 Complexes containing DTPA (Magnevist) and DOTA ligands (Dotarem) are 
ionic, while BMA-DTPA (Omniscan) and HP-DOTA (Prohance) ones are 
neutral. Structures of Gd complexes approved for clinical uses are shown in 


































































































Figure 1.2. Structures of approved Gd(III) complexes. 
 




Their low osmolarity decreases the pain of the injections. All these 
agents are extracellular, and they diffuse rapidly into the interstitial space. The 
Gd(III) center is nine-coordinate in each complex and it contains one bound 
H2O ligand. Water exchange on Gd(III)  is dissociative and steric crowding at 
the H2O site enhances the exchange rate. 
Magnevist does not enter in cells and is excreted almost exclusively by 
the kidney. Introduction of a benzyloxymethyl substituent on the a-C atom of a 
terminal acetate of DTPA as in BOPTA produces a Gd(III) complex 
Gadobenate (MultiHance). It enters hepatocytes and is excreted in bile.
.(9,10) 
The coordination sphere of Gd(III) in Gadobenate is almost identical to that in 
Magnevist (nine-coordinate, distorted tricapped trigonal prism), and both 
complexes have similar stabilities and relaxivities.
(10)
 
Mangafodipir (figure 1.3), known also with the brand name of 
Teslascan or as mangafodipir trisodium 
(11)
 is a contrast agent delivered 
intravenously to enhance the contrast during the MRI. It has two parts: 
paramagnetic manganese (II) ion and the chelating agent fodipir (dipyridoxyl 
diphosphate, DPDP). The distorted octahedral complex is used in clinical 
diagnosis to enhance contrast in the liver and to detect hepatocellular 
carcinomas).
(12) The relaxivity of this complex is about 35% higher than Mn 







































Figure 1.3. Structures of Mangafodipir 
 
 
























Re are β-emitters. Several of these radionuclides centers are 
used for diagnostic imaging and for therapy
(14)
. Nuclear medicine has grown 
mainly to the availability of 
99m
Tc radiopharmaceuticals; this isotope is used in 
over 80% of all diagnostic procedures. 
The first generation of technetium radiopharmaceuticals was developed 
mainly thanks to these proprieties of the common complexes of 
99m
Tc: 
absorption, distribution, metabolism and excretion. These studies led to 
99m
Tc 




), the liver (
99m
Tc-
colloids), the bone (
99m





The modern analytical tools, such as nuclear magnetic resonance 
spectroscopy, mass spectrometry and X-ray diffraction, helped researchers to 
understand the structure-activity relationships underlying the biological 
behavior of the 
99m
Tc agents for their ability to determine the exact molecular 
structure of coordination compounds. Therefore, the precise design of new 
ligands and their 
99m
Tc complexes led to discovery imaging agents for 
perfusion in the myocardium and brain. The cardiac imaging agents 
99m
Tc-
MIBI (sestamibi, Cardiolite®) and 
99m
Tc-tetrofosmin (Mvoview®) and the 
brain imaging agents 
99m
Tc-HMPAO (exametazime, Ceretec®) and 
99m
Tc-






Cardiolite® is used for myocardial perfusion imaging. Lipophilic cationic 
complexes imitate potassium ion and are taken up by the myocardium. 
Therefore the complex structure was designed
(17) 
on the basis of this principle. 
The sequential metabolism of the six identical methoxy groups and of eight to 
hydroxyl groups in the liver leads to formation of 
99m
Tc complexes with higher 
hydrophilicity which are not retained in myocardial tissues
.(18)
.  




While Ceretec® is an approved cerebral perfusion imaging agent for 
evaluation of stroke. It is taken up by the brain and is transformed into more 
hydrophilic species which are retained in the brain.
 
Current designs of imaging agents are based on the careful selection of 
the suitable biomolecules to function as effective vectors. It concerns in vivo 
delivery of radioactivity to more specific biological targets such as receptors 
and transporters.  
This strategy implies that the method of marking must not induce any 
distortion in the active site of the biomolecule. Thus, these agents have 
required the development of sophisticated marking methods that go beyond 
the technologies used previously. 
The introduction of the bifunctional chelating agents (BFCA), the new 
chemistries such as the Tc-tricarbonyl, Tc-nitrido, Tc-HYNIC and mixed 
ligands complexes have helped to achieve this objective. 
(7)
 
Monoclonal antibodies (mAbs) conjugated with radionuclides are used 
clinically for diagnosis of colorectal and ovarian cancer such as 
111
In 
satumomab pendetide, which contains the murine mAb B72.3 and is directed 
to TAG-72, an antigen expressed by many adenocarcinomas.
(19)
 There are 




In in clinical trials.
.(20)
 





Encapsulation in fullerenes 









1.3 Superoxide Dismutase Mimics 
 
Oxidative damage is an inevitable side effect of cellular metabolism 
and it is the cause of systemic aging and genome instabilities such as telomere 
shortening, mitochondrial mutation, and chromosomal pathologies. Reactive 
Oxygen Species (ROS) are also one of the major causes of degenerative 
diseases affecting the elderly. 
(7) 
 
The free radical superoxide, O2
-
, is a product of activated leukocytes 
and endothelial cells. It is a mediator of ischemia-reperfusion, inflammatory 




The metalloenzyme superoxide dismutase (SOD) can destroy O2
-
:. Cu-
SOD and Zn-SOD are found in the cytoplasm of eukaryotic cells, while Mn-
SOD is located in mitochondria (figure 1.4)  
 
M
n+1   
+  O2
-                                 
M
n+ 






+                                 
M
n+1 
+ H2O2 (2) 
Figure1.4. Superoxide dismutase reactions. 
 
MnSOD mimics have been designed for laboratory synthesis by 
computer-assisted modelling.  
Intramolecular electron transfer requires Mn(II) in the active site of the 
enzyme. Mechanistic studies confirmed that during catalysis the ion can 
reduce binding-energy barrier and help to bind ligands in a correct geometry. 
A series of active Mn(II) macrocycle compounds have been designed and two 
are now in clinical trials.
(24)
 
Also Catalase mimics appear to require Mn(III) in the “active site”. A 
series of manganese complexes that are mimetic of both superoxide dismutase  




and catalase have proven to be active in rodent models as synthetic catalytic 
scavengers of ROS (Figure).
(25)
 
The use of these molecules in therapy is limited by their short plasma 
half-life because they endured clearance by the kidney and by their inability to 
penetrate cell membranes; in fact they have only an extracellular activity. Low 
molecular mass mimics of SOD are molecules with potential pharmaceutical 
interest.
(26) 
For example, a variety of Mn and Fe-based on porphyrins and 







macrocycles appear particularly promising.
(31, 32)
 For example, SC-52608 
(figure 1.5) is able to scavenge superoxide and to protect effectively 















































































Figure 1.5. Structures of manganese complexes tested as mimetics of 
superoxide dismutase. 
 
Instead, Manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)-porphyrin 
(MnTBAP) can protect against neurodegeneration. It is studied for the 
treatment of brain diseases such as Parkinson’s and Alzheimer’s diseases.
(34) 
  




1.4 Platinum anticancer drugs 
 
Chemotherapy is more widely used than surgery and radiotherapy in 
treatments for cancers.  
Cisplatin (23, figure 1.6) or cis-diamminedichloroplatinum(II) (DDP) 
is considered the successful historical example of a metal-based drug since it 
was discovered by Rosenberg et al.
(35)
 Platinum complexes are used in a lot of 
solid tumors such as lung tumor, colorectal tumor, ovarian tumor, head and 
neck cancer, genitourinary cancer and breast cancer 
(36, 37)
  
The glycolato complex (nedaplatin, 25) and oxalato complex 
(oxaliplatin, l-OHP, 26 , which contains R,R-1,2- diaminocyclohexane, 
DACH) are approved for clinical use respectively in Japan and in France. 
Particularly they are used in multi-drugs chemotherapy for treatment of 
advanced lung, colorectal, and ovarian cancers.


































Figure 1.6. Structures of platinum complexes clinically approved. 
 




Platinum derivatives are alkylating agents. Cisplatin by diffusion enters 
in the cells where it is converted into the active form. Scientists have not 
determinate the active species with great precision. They believe that the 
active species is the monohydrate even if the most common species is the 
dehydrate form. The main function of the cisplatin is to bind itself to the DNA. 
In fact, although cisplatin is able to interact with many types of vital proteins 
for DNA replication and cell division, the main target remains the DNA.  
Cisplatin, Carboplatin and oxalilplatino enter in the cells thanks to an 
active conveyor of the CU
2+
 - the CTR1 (copper transporter 1) - causing the 
degradation at the same time. The extrusion of these compounds occurs by 
active transport mediated by the conveyors of copper, ATP7A and ATP7B, 
and by the MRP system1 (multidrug resistance protein 1).
(40)
 Inside of the cells 
the binders chloride of cisplatin are offset by water molecules producing 
strongly reactive molecules. Guanine N7 is the electron-richest site on DNA. It 
represents the most important binding site in the nucleic acids. The complexes 
of platinum activated react with the nitrogen in position 7 of guanine on DNA, 
causing the formation of guanine-guanine crosslinks. 1,2-GpG and 1,2-ApG 
crosslinks are the major adducts of platinum drugs with DNA. These ones 
inhibit the processes of replication and transcription and lead to breakage of 
single and double-stranded. Moreover they determine coding errors 
(miscoding) which are recognized by proteins of cell cycle control 




Platinum complexes possess considerable toxicity and numerous side 
effects. One of the main effects is the nephrotoxicity. Cisplatin may in fact 
cause renal damages: tubular degeneration, necrosis and mineralization of the 
epithelial tubular cells. Another effect is ototoxicity that arises especially in 
children. Ototoxicity leads to loss of hearing capacities. The initial symptom  




includes chiming (ringing in your ears). These effects should stop at the end of 
the treatment, but some patients lost irreversibly the use of hearing over the 
high-frequency range (> 4KHz).  
Other toxic manifestations such as nausea, vomiting, decrease in red 
blood cells, tingling in the hands and feet are also common of other antitumor 
drugs. The neurotoxicity of the drug manifests itself particularly in high doses, 
while decreases in platelets, facial swelling, dyspnea (shortness of breath), 
muscle cramps, blurred vision and loss of appetite are less common. Nausea 
and vomiting occur normally about an hour after the administration of the drug 
and they can last for several hours.  
In addition as other drugs that form adducts with DNA, platinum 
complexes are associated with the onset of acute myelocytic leukemia even 
after 4 years from the treatment.
(42)
 
Despite the use of these compounds in many multi-drug treatments 
there is a large interest in developing novel compounds that exhibit innovative 
characteristics in respect to the existing ones. The research activity is on time 
for the development of novel compounds. In addition to determining a minor 
systemic toxicity they should ensure a marked antineoplastic activity even for 
the tumor lines that have proved resistant. In order to achieve these objectives 
we began to design and to study metal complexes which possess in their 
structures metal centres different from platinum. 
Pt–NHC complexes have been highlighted as a promising and original 
platform for building new cytotoxic drugs of the cisplatin series. 
(43-48)
 
Mixed NHC–amine Pt(II) complexes were prepared through modular 
two-step sequence leading to trans-configured square planar species by 
Marinetti et al.
(47)
. Their efficiency against both cisplatin-sensitive (CEM and 
H460) and -resistant (A2780/DDP, CH1/DDP, and SK-OV-3) cell lines was 
demonstrated by in vitro experiment. All novel complexes exhibited cytotoxic  




activities with IC50 at a micromolar range. IC50 of the measured complexes 
against CEM T leukemia cells was in the 0.6–2.7 mM range, generally lower 
than that of cisplatin (3.0 mM) under the same experimental conditions. Some 
of the complexes outperformed cisplatin against H460 lung cancer cells, too. 
This study afforded a potent and innovative new chemical platform for 
cytotoxic drugs of the Pt(II) series based on NHC ligands.
(47) 
  




1.5 Ruthenium complexes 
 
The first metal that arouses the interest of the scientific community 
with regard to the design of complex innovative anticancer was the ruthenium. 
Scientists believe that the ruthenium and platinum, sharing the same group on 
the periodic table of the elements, have the same antitumor effect that is a 
direct interaction with the DNA comparable with cisplatin.  
However, subsequent studies have demonstrated that complexes of 
ruthenium(III) have actually distinct properties from those of the platinum. 
These compounds tend to accumulate more and more in neoplastic cells 
exploiting a transport system mediated by transferrin. In this way they have a 
certain degree of specificity while it is absent in the complexes of platinum. In 
fact, the ruthenium is able to mimic the iron by binding to the protein 
transferrin. The cells in rapid division, including tumor cells, require a greater 
amount of iron. This process translates into an up-regulation of receptors for 
transferrin on the cell membrane and a greater uptake of these complexes from 
the blood. In addition, before reaching the tumor mass, complexes of 
ruthenium(III) are inactive and their bio-activation is performed by reduction 
of the metal centre to ruthenium(II), favoured by the low levels of oxygen and 
by the high acidity of the tumor environment.
(49)  
Currently, two complexes of ruthenium(III) trans-
[RuCl4(Im)(DMSO)]ImH (NAMI-A) and trans-[RuCl4(Ind)2]IndH (KP1019) 
are in clinical trial phase. Their structures are shown in figure 1.7. 
Both complexes of Ru(III)
+
 are formed by a heterocyclic counter-ion, 
heterocyclic ligands and binders chloride. Despite their structural similarities, 
these complexes differ greatly for their antitumor activity profile.  
 
 


























Figure 1.7. Complexes of Ruthenium studied in clinical trials. 
 
Preclinical studies have shown that nami-A is able to inhibit the 
formation of metastases in different tumor animal models but it does not show 
cytotoxic direct effects. On the contrary KP1019 has shown antitumor effects 
directed against a wide range of xenografts tumor, through the induction of 
apoptosis.
.(50-55)
 The mechanisms of action proposed for the nami-A compound 
include: the interaction with the processes of regulation of the cell cycle 
(accumulation of cells in the G2/M phase); the alteration of the functions of 
endothelial cells required for the process of angiogenesis and the increase of 
the extracellular matrix around the blood vessels that irrigate the tumor and 
direct interaction with the nitrogenous bases of DNA. The mechanisms 
involved in the process of apoptosis induced by compound KP1019 include 
interference with the chain for the transport of the electrons, depolarization of 
the mitochondrial membrane and down-regulation of anti-apoptotic bcl-2  




factor. The compound is also able to interact directly with the DNA, but this 




Thus, the activity of other Ru(II) complexes is currently being 
explored. For example, arenes are known to stabilize ruthenium in its 
oxidation state (2
+
), therefore the potential of Ru(II)–(6-arene) complexes as 
anticancer agents is under investigation 
(55,57,58)
. In literature we can found 
several studies about half-sandwich (6-arene)Ru(II) complexes with 
imidazole, sulfoxide, phosphane, chelating aminoacids, and diamine or 
diimine ligands. All these molecules was evaluated for cytotoxic activity. Both 
the size of the arene and the lability of the Ru–Cl bond have found to play a 
crucial role in determining the cytotoxicity of ruthenium(II) complexes of the 
type [(6-arene)RuCl(LL´)](PF6) with bidentate ligands LL´. Compounds with 
extended polycyclic arenes (e.g. tetrahydroanthracene) and 
LL´=ethylenediamine (en) are the most active of A2780 human ovarian cancer 
cells, whereas those with polar substituents on the arene such as COOCH3 (an 
electron-withdrawing group) or with aromatic diimine ligands such as 2,20-
bipyridine or 1,10- phenanthroline exhibit either poor or no activity. 
  




1.6 Metallocene and Titanocene complexes 
 
In recent years new anticancer drugs containing a metal different from 
platinum have been developed. The objectives of these research were the 
improving of the clinical efficacy, the reducing the toxicity and the 
overcoming of drug-resistance, all own limitation of platinum derivatives. 
Obviously the broadening of the spectrum of action of platinum complexes 
was a good reason for making research in this context.
(59)
 The research has 
focused on transition metal complexes bearing as binders chlorides in cis or 
like labile ligands. Among the drugs the metallocene complexes of the type 
(C5H5)2MCl2 received many attentions because they represented a logical 
extension of cis-platinum derivatives 
(51) 
. These complexes are constituted by 
a metal core, formed by metals transition such as Ti, Nb, Mo, etc. The 
coordination sites of the metal are occupied by two cyclopentadienyl rings 













 have investigated the antitumor activities 
of a whole series of metallocene dichloride complexes in vivo, after the 
variation of the transition metal. From this research, titanocene dichloride  
 
 




(TDC) (figure 1.9) exhibited the most promising chemotherapeutic activity 
among all other metallocenes tested.
(61.)
  
In fact, titanocene dichloride (Cp2TiCl2) showed medium 
antiproliferative activity in vitro, but promising results in vivo.
(62,63)
 
Really titanocene dichloride was the first metal-based 
chemotherapeutics to reach Phase I clinical trials from the development of 
cisplatin. However it showed promising in these preliminary studies, it did not 
progressed beyond Phase II due to its low efficacy vs. toxicity ratio 
(64,65)
. 
Unfortunately its efficiency in patients with metastatic renal cell carcinoma or 
metastatic breast cancer was too low to be pursued. 
(66,67) 
The anticancer properties of cis-diethoxybis (1-phenylbutane-1,3-
dionato) titanium(IV) [(bzac)2- Ti(OEt)2, known as Budotitane were first 
reported in 1982.
(68) 
It possesses activity towards animal tumors such as EAT 
and colon tumors.
(69,70) 
Also the budotitane (figure 1.9), due to its good 
biological results in preliminary studies, reached Phase I of clinical trials, but 
it did not progress in Phase II due to formulation problems.
(70) 
These 
difficulties have spurred the development of titanium complexes that display 



























Budotitane Titanocene Dichloride 
 
Figure 1.9. Structure of Titanocene dichloride (TDC) and Budotitane. 
 
Titanocene dichloride does not bind with nucleotides and nitrogen 
bases, as the cis-platinum, but its mechanism and the biological action, as 
proposed by Sadler e co-workers on the basis of model studies, provides that 
titanium species could be complexed to phosphate and gives interaction with 
DNA.
 
The titanium (IV) ion, by binding to specific sites of the iron (III), forms 
a strong complex with the transferrin, a protein of human plasma, and is thus 
supplied to tumor cells. 
(71)
 
The interesting results obtained with Cp2TiCl2 encouraged researches to 
develop new complexes of this metal which might have higher hydrolytic 
stability and higher cytotoxic activity.
11
 In fact, in order to improve these 
properties of titanocene derivatives, polar side chains were attached to the Cp 
ligands. Titanocenes complexes, having polar substituents on cyclopentadienyl 
ring, such as alkoxy, amino or electron-withdrawing groups as carboxylic acid 
and esters, showed, in some cases, a very high activity in antitumoral tests.
(72-
76) 
 Highly substituted ansa-titanocenes, containing a carbon-carbon bridge,  
 






 although, generally, higher activity was found 
in analogues where the two Cp units were not bound together.
 (82,83) 
A lot of analogues of titanocene containing aromatic groups linked to 
the Cp have been synthesized.
(84)
 One of the most interesting of this series, in 
the pharmacological field, is bis-[(p-methoxybenzyl)cyclopentadienyl]-
titanium-dichloride (titanocene Y) shown in figure 1.10. 
Its antiproliferative activity was studied in 36 human tumor cell 
lines
(85)
 and in human tumors explanted.
(86-89)
 The most significant results of 
these experiments in-vitro and ex-vivo had with the tumor cells of the prostate, 
cervix and kidney. Furthermore, titanocene Y was tested on breast cancer cell 
line MCF-7 revealing a promising medium-high cytotoxic activity with IC50 
values of 76 M, quite close to those of the cis-platinum (37 M).
(90)  
 








Figure 1.10. Structure of Titanocene Y 
 
Furthermore, replacing the two titanocene Y chlorides with an oxalate 
group by a simple reaction of anion exchange, it is obtained a product that has 
a greater hydrolytic stability, due to the chelating effect of oxalate group and it 
shows an activity 13-fold higher than the titanocene Y in-vitro studies on the 
cell line LLC-PK.
(91)








1.6.1 Metoxy-aryl and alkyl titanocenes 
 
Recently our studies reported the synthesis and cytotoxic activity of 
some titanocene complexes that they have substituents on cyclopentadienyl 
rings able to intra-molecularly coordinate the titanium cation, stabilizing the 
active species. The complexes showed very interesting antiproliferative 
activity on several cancer cell lines.  
In particular we replaced the methoxy-aryl substituent of 
cyclopentadienes of titanocene Y with ethenyl-methoxy in the way of having 
the presence of a strongly coordinating group, able to stabilize the cationic 
species responsible for cytotoxic activity. We also verified, by substitution of 
chlorine atoms with dimethylamide, oxalate, or amino groups, the influence of 
other ligands leaving on the activity of the complexes.
(93) 
Some of the synthesized compounds showed a good cytotoxicity, in 
particular the complex bis-ethenylmethoxyl-cyclopentadienyl-titanium 
dichloride (T2) and ethenylmethoxyl-cyclopentadienyl titanium trichloride 
(T1), see Fig. 1.11, on the cell line MCF-7 displayed IC50 values (84 and 57 
µM, respectively) very close to those obtained with the cis-platinum and to 
that reported for the titanocene Y. Furthermore, the results of the hydrolysis of 
our titanocenes shown that the leaving groups (-Cl, -N(CH3)2, C2O4 or glycine) 
influencing the rate of hydrolysis of the ciclopentadienyl groups and thus the 
stability of the complexes. 
(93)
 
Therefore, the presence of substituents, aryl methoxy group on 
cyclopentadienyl ring in titanocene Y or ethenyl-methoxy group in titanocene 
T2 or in the half-titanocene T1, produces compounds having interesting 
cytotoxic activity (figure 1.11).  
 
 

















Figure 1.11. Structures of bis-cyclopentadienyl-ethenylmethoxyl-titanium dichloride 
T2 and cyclopentadienyl-ethenylmethoxyltitanium trichloride T1 
 
Although generalizations regarding structure-activity relationships are 
not yet clear, we could hypothesize that the neutral nucleophilic substituents of 
cyclopentadienyl (aryl methoxy or ethenyl-methoxy group) could 
intramolecularly coordinate to the titanium cation, thus preventing 
decomposition reactions. On the other hand, this hypothesis was suggested for 
analogous complexes able to give polymerization of propene or styrene having 
microstructures strongly influenced by the possible coordination of neutral 
substituent of cyclopentadienyl at the metal center.
(94-96) 
As mentioned above, in the literature several examples of titanocene-
complexes showing cytotoxic activity are reported, the cyclopentadienyl-
ethenylmethoxyl-titanium trichloride represents the first example of half-
titanocene complex having this interesting cytotoxic activity.  
Therefore, a series of novel half-titanocenes compounds were 
synthesized and characterized (see figure 1.12) by nuclear magnetic resonance 




















































Figure 1.12. Structures of synthesized half-titanocenes. 
 
These complexes had different substituents on the Cp ligands, able to 
stabilize the titanium cation by intramolecular coordination. Preliminary 
cytotoxic studies of these titanium based compounds evaluated their growth 
regulatory effects in MCF7 and SkBr3 breast cancer cells. Several agents 
showed a moderate or a high antitumor activity. For example, 4b showed the 
strongest antiproliferative activity against MCF7 breast cancer cells, whereas 
5b showed a very interesting activity against SkBr3 breast cancer cells (see 
figure 1.13).  
In order to understand if a different group can influence the 
intramolecular coordination and consequently the stability of the complexes  




and if the ether group is really essential for cytotoxic activity, several new-
titanocene complexes (see figure 1.14) were synthesized and characterized 
having as ligands the 2-cyclopentadienyl-ethoxy-benzene [Cp-CH2CH2-O-Ph] 
or the cyclopentadienyl-benzyl [Cp-CH2-Ph]. Then their cytotoxic activities on 




Figure 1.13. Evaluation of growth responses to 10 µM of 1b-6b in MCF7 (a) and 


























































DC6 was synthesized to verify if a phenoxy group, instead of methoxy 
group present in T2, could better stabilize the titanium cation. In fact this 
ligand may stabilize either with oxygen atom or with phenyl ring. DC6-oxalate 
and DC6-gly were synthesized to achieve different leaving groups, respect to 
chloride, on titanocene, which possibly could improve the activities of the 
complexes, by favorable pharmocokinetic properties.  
ES2 was synthesized to prove if the ether group, which is present on 
titanocene Y, on T1 and T2, as well as on T2, was really necessary to have a 
cytotoxic activity significantly higher than Cp2TiCl2, or if a more labile ligand, 
having higher capability to π-donation can produce a molecule as much as 
pharmacologically interesting. ES2-chelated could have the same properties of 
ES2, but this ansa derivative, having the two cyclopentadienyl rings 
covalently linked, should be less stable and possibly to have lower activity 
than ES2.  
Preliminary cytotoxic studies of ES2 compound, in order to evaluate their 
growth regulatory effects in MCF7 and SkBr3 breast cancer cells were carried 
out. The results were very interesting because this complex showed strong 
antiproliferative activity on both cell lines (see figure 1.15).  
 
 
Figure 1.15: Evaluation of growth responses to 10 µM of ES-2 in MCF7 (a) and 
SkBr3 (b) breast cancer cells, as determined by using the MTT assay. 




Several titanium complexes were synthesized and tested for their 
cytotoxic activity against cancer cell lines. Most of these compounds showed 
significant anti-proliferative effects compared to cisplatin 
As indicated by these researches the presence of a coordinating group, 
such as phenyl or ether one, is necessary to stabilize the active species, delay 
hydrolysis and generate a cytotoxic complex; the ether groups are important to 
improve the hydrolysis stability but are not necessary to have a significant 
cytotoxic activity; a more labile ligand, as the benzyl group, having greater 
ability of π–donation, produce complexes with interesting cytotoxic properties; 
a lower activity was found in the analogues where the two Cp units were 
bound by a two-carbon bridge. 
Half-titanocene showed lower cytotoxic activity compared to their 
titanocene analogues; the labile ligands (Cl) do not have a strong impact on 
cytotoxic activity; a methyl group on the linker between Cp ring and the 
phenyl group decreases the cytotoxic activity; a small steric hindrance all 
around the complex is favoured; the pro-ligands show interesting cytotoxic 
activity but are not related to complexes cytotoxicity; further studies are 
needed to understand the exact mechanism through which these compounds 
exercise their action. 








1.7 NHC complexes in medicine. 
 
The chemotherapy, flanked to surgery and radiotherapy, is used for the 
treatment of cancer. Moreover there are numerous metals (Ag, Au, Cu) with 
binders carbenic N-heterocyclic groups that were studied in the 
pharmacological field. 
 
1.7.1 Ag-NHC complexes 
 
Silver has been since antiquity used as antimicrobial agent, it was 
earlier employed in the purification of drinking water, wine and vinegar, and 
also Hippocrates remarked its therapeutic properties.
(97)
 To our days the silver 
salts are still used for example to treat chronic ulcers, burns extended, to 
prevent conjunctivitis in the new-born and in so many other infections.
(98)
 
The activity of silver against Gram-positive and Gram-negative 
bacteria, fungi and yeast is due to Ag
+
 cations, which can interact with the cell 
membrane, interfere with the electron transport system of the cell and interact 
with thiol groups of the vital enzymes of bacteria. 
(99)
 
However the objective, in order to have a good therapeutic action 
antimicrobial, was to provide agents that released slowly and continuously the 
ion Ag
+
 in the affected area. In fact, the already known salts of silver nitrate or 
sulfadiazine silver, for example, (Figure 1.16), while having an antibacterial 
topical action, expose the subject to a relapse precisely because of the rapid 
release of the Ag
+ 
and then have a rapid effect but not durable in combat 
infection. 
Scientists tried therefore to synthesized stable complexes that could 
slowly release the ion in time. The choice of a suitable ligand, bonded to the 
metal, can make the difference. 
















Figure 1.16. Structures of Sulfadiazine (A) and silver nitrate (B). 
 
The use of the complexes Ag-NHC that show a bond C-Ag relatively 
strong to generate a more stable complex compared to previous silver-based 
drugs is the subject of numerous research.
(100)
 
The Ag-NHC can be synthesized by three synthetic approaches. The 
first provides for the treatment of the NHC with appropriate "sources" of silver 
at the temperature of liquid nitrogen. The second consists in treating 
compounds of silver as Ag2O, AgOAc or Ag2CO3 with the salt of the NHC at 
room temperature or warm. The last method envisages the transfer reaction of 
step in basic conditions between the silver salt and salt NHC. The second 
approach is the most common and used because it is more convenient too. 
(101)
 
The Ag-NHC were also tested to evaluate their antitumor properties 
and has been highlighted cell death by apoptosis without developing necrosis. 
For these complexes the suggested action mechanism provides the 
depolarization of the membrane potential of mitochondria with consequent and 
probable release of mitochondrial proteins that provide to the apoptosis. 
Complexes did not cause overproduction of oxygen reactive species (ROS) 
and activation of caspase-3, while instead occurred translocation of apoptosis 
inductor factor and caspase-12 in the nucleus. These events promoted the 
DNA fragmentation and finally cell death. Therefore, complexes were not 
genotoxic because they did not change the distribution of the cell cycle.
(102)
  




To further improve the release scientists encapsulated these silver 
complexes. This would also prevent the degradation at the level of the 
bloodstream in which there is present the chloride ion, which by interacting 
with Ag-NHC, it would cause the precipitation. For some complexes of Ag-
NHC this encapsulation was made with poly (lactic-co-glycolic acid) 
combined with polyethylene glycol, and receptors of the folic acid were used 
to allow the delivery in a tumor site. Some of the various nanospheres 
prepared and loaded with complex Ag-NHC were then tested against MB157 




Good results are obtained with the saturated Ag-NHC and this has 
pushed to investigate the activity of unsaturated NHC and substituted in 
position 4 and 5 of the imidazole ring. In particular the effect of electron-
attractor of chlorine atoms in position 4 and 5 determines a better stability of 
the relative complex Ag-NHC compared with a similar no-chlorinated.
(104)
 
This category of silver complexes derived from 4,5-dicloroimidazolo showed 
a certain degree of selectivity toward the ovarian cancer (OVCAR-3) and of 
the breast cancer (MB-157).  
Scientists demonstrated in vivo activity of the complex 1, shown in 
figure 1.17, against a model of xenotransplantation ovarian cancer. Gautier 
Morel reported in the literature as the carbene N,N-diaryl-substituted, with its 
high lipophilicity, could be a good binder for metal complexes 
pharmacologically interesting indeed the cytotoxicity of the resultant 
complexes of silver was 40 times on MCF-7 and HL60 and 7 times on MCF-
7R is higher than that of cisplatin. 
The good obtained results pushed research in this direction and it was 
found that in order to obtain a high degree of accumulation in tumor cells, the 
aromatic rings of the metal complex must be substituted in position 2, 3 and 4  




as follows: 2-F, 3-F, 4-F, 4-OH or 4-OCH3. These substitutions have already 
been made on the complex 1,2-diariletilenediammino platinum(II) for which 




























Figure 1.17. Selected complexes of silver-NHC and 2,4,5 - triarylimidazoles. 
 
1.7.2 Au-NHC complexes 
 
The gold was, and still is, used in various biomedical applications such 











The two lead structures from which it started to develop new 
chemotherapeutic agents based on gold are the auranofin and its analogue 














Figure 1.18. Lead structures based on gold. 
 
Studies into structure-activity relationship highlighted the importance 
of fosfinic portion while replacing the carbohydrate or of the halide in the 
respective molecules does not induce loss of activity. In recent years, however, 
the discovery of the NHC was exploited also in the field of biology. They have 
proved to be effective alternatives to phosphine precursors
(119)
, thanks to the 
capacity σ-donor comparable to that of the phosphine ligands and the ease 
with which they can be carried out the structural modifications to the nitrogen 
atoms . 
As well as the auranofin and its analogue Et3PAuCl induce apoptosis 
through inhibition of the enzyme thioredoxin reductase (TrxR mitochondrial), 
in the same way the Au-NHC cause the death of sun cancer cells.
(120)
 This 
would be justified by assuming a certain affinity between the complexes based 
on Au and involved enzymes. The system thioredoxin/thioredoxin reductase 
(Trx/TrxR) is involved in the regulation of processes intracellular redox. The 
scheme of action general of TrxR is reported in figure 1.19. 
 
 




Tioredoxine, depending on the redox potential of its substrate, 
catalyses the reversible reactions that involve the formation or breaking of the 
disulphide bonds.  
Thioredoxin is involved both in the defence against oxidative stress 
that in apoptosis; in particular it has been postulated to the formation of the 
complex protein in reduced form and kinase apoptosis signal 1 (ASK1) as 
responsible for the inhibition of apoptosis.
(121) 
 






Figure 1.19. Activities of reduttasica TrxR system/NADPH. 
 
The TrxR has in the N-terminal portion a peptide sequence of the type 
cysteine-AA-AA-cysteine and the C-terminal portion of a sequence of the type 
selenocysteine-AA-AA-cysteine (where AA are amino acids different from 
cysteine). The presence of the atom of selenium justifies the affinity of the 
gold atom of the complex for this enzyme and in more considering that cancer 
cells show an increased metabolism, you may also explain the over-expression 
of this enzyme in this type of cell. Consequently the selective inhibition of this  
 




type of enzyme is one of the parameters on which it bases for developing new 
chemotherapeutic drugs based on gold.
(122)
 The inactivation of TrxR, due to 
the formation of a covalent bond with the selenium atom of the enzyme
(123)
, 
determines an increase of thioredoxin in oxidized form that induces cell death 
as shown in figure 1.20. 
 
 
Figure 1.20. The molecular mechanisms involved in the induction of the apoptotic 
process caused by the complex of gold. 
 
The lack of thioredoxin in reduced form involves less inhibition of 
ASK1 kinase for which there is the activation of the cascade of mitogen-
activated protein kinase (MAPK), between which the c-Jun N-terminal kinases 
(JNK) and p38, which stimulates the apoptotic process. Added to this there is  
 




the lesser capacity of TrxR to maintain in the reduced state proteins that play 
important roles in the cell as the Perossiredossina (Prx), favoring the 
accumulation of reactive oxygen species (ROS), in particular of hydrogen 
peroxide, and thus generating a strong oxidative stress. The oxidating 
environment created further contributes to the oxidation of thioredoxin and 




However considering the great structural variety of binders it is not 
possible to define an univocal mechanism of action. In fact the gold 
compounds can trigger the apoptosis by various processes: mitochondrial 
damage that provides for the inhibition of thioredoxin reductase (TrxR) direct 
DNA damage, modification of the cell cycle, inhibition of the proteasome, 
modulation of specific kinase and other cellular processes.  
An important factor for the targeting of malignant cells is represented by the 
possibility to adjust the lipophilicity of relevant complexes. In fact it has been 
shown an antimitocondrial effect which is manifested with swelling of these 
organelles, much faster because the greater the lipophilicity.
(125) 
The lipophilic cation delocalized (DLCs) can move quickly the lipid 
bilayer and focus on mitochondria guided by the increase of the membrane 
potential generated in turn from the respiratory chain. These DLCs is mainly 
concentrated in the mitochondria of cancer cells precisely as a result of the 
high potential of the membrane that is a characteristic of many tumor cells. 
Therefore the modulation of the lipophilicity might be an idea to generate a 
certain degree of selectivity toward the cancer cell than normal.  
Furthermore the selectivity toward the tumor cell is an important 
parameter. In fact tumor cell shows an increased activity of TrxR, responsible 
of evasion of apoptosis. The inhibition of this enzyme can induce the cell 
apoptosis. The TrxR is considered an important target for this category of  




drugs. Many compounds proved to be potent inhibitors of the purified TrxR 
enzyme, but few could inhibit it the cell.
(126) 
 
1.7.3 NHC-Cu complexes 
 
The coordination compounds of Cu(I, II) have been investigated as 
potential antitumor agents only in the last few decades, particularly after the 
discovery of cisplatin, although copper has a long history of medical 
application.
(127-132) 
The complex Cu-NHC have been little studied from a biological point 
of view. The copper however, being important for the correct functionality of 
numerous enzymes and proteins and being involved in a series of 




Recently a series of copper complexes was tested with regard to their 
own cytotoxicity and some have shown good antitumor activity both in vitro 
and in vivo. It has been demonstrated that the copper compounds may act 
through different mechanisms than those of cisplatin and the DNA would not 
represent the biological target main or however would not be the only 
molecular target for this class of molecules. In addition to the binding to DNA, 
the intercalation and the cleaving activity, these compounds can create damage 
cellular oxidative thanks to similar activities that show with superoxide 
dismutase and ROS generation after reaction with oxygen and intracellular 
peroxide. These are all events intracellular molecular that trigger the death of 
tumor cells through an apoptotic mechanism. Furthermore, for these copper 
compounds, an adjustment of the proteins antiapoptotic (Bcl-2 and Bcl-XL) 
has been highlighted on the tumor cells . This leads to the death of cancer cells 
through a programed cell death mechanism known as apoptotic paraptosi that  




can be exploited for lead to death even those tumor cells with defects in the 
normal process of apoptosis as, for example, cells cisplatin resistant.
(102) 
The effect of complexes of copper-NHC reported in figure 1.21 was 
evaluated on the cell line MCF-7 (breast cancer). 
All candidates, except the complex 14 that from a structural point of 
view is the most taken up, showed IC50 values lower than the micromolar and 



















Figure 1.21. Cu-NHC selected for biological studies. 
 
 




Table 1. IC50 of the complexes Cu-NHC on cell line MCF-7 (μM). 
Cisplatin 10 11 12 13 14 
10,4µm 0,075µm 0.13µm 0,04µm 0,075µm 4,4µm 
 
 
Due to greater activity the assembly 10 has been the object of further 
studies. In particular were evaluated the possible effects on cell cycle and it 
has been found a stop in step G1 at concentrations at least ten times lower than 
those of cisplatin (DDP). 
Moreover, genotoxicity studies conducted using enveloped plasmids 
have demonstrated, as expected, that complexes of copper(I)-NHC, compared 









1.8 Mammary carcinoma 
 
The mammary carcinoma is a malignant disease characterized by the 




Breast tumors represent, as a whole, the type of tumor most frequently 
diagnosed among women of all ages: 0-49 years (41%), 50-69 years (36%), 
≥70 years (21%). It is the neoplasia more diagnosed in women in Italy (29% of 
all cancers diagnosed) and represents the first cause of oncological death. 
Risk factors for the onset of breast carcinoma is associated with several risk 
factors:  
 Age. 
 Previous thoracic radiotherapy.  
 Previous pathologies implants (dysplasia or cancer of the breast tissue).  
 Menarche early and late menopause.  
 First pregnancy at term in advanced age (> 30 years).  
 Failure to breast-feeding. 
 Lifestyle (obesity, poor physical activity, high consumption of alcohol, 
carbohydrates and saturated fats). 
 Hormone replacement therapy. 
 Familiarity and genetic factors: mutations of genes BRCA-1 and 









Mutations of genes BRCA-1 (breast cancer susceptibility gene 1), 
located on chromosome 17, and BRCA-2 (breast cancer susceptibility gene 2), 




The products of gene expression of BRCA1 and BRCA2 are two 
proteins involved in the reparative response mobile phone as a result of 
damage to the DNA. Mutations at the expense of these genes can determine an 
altered expression of these proteins or the expression of proteins with altered 
functionality, thus arranging the individual at the onset of neoplasias. The 
carcinomas related to mutations of genes BRCA-1 and BRCA-2 and familiar 
tend to occur at a younger age, with respect to the sporadic cases, although the 
increased risk related to the presence of these mutations persists throughout 
life. 
 
1.8.2  TNM classification  
 
The TNM system is the international system of classification of a 
tumor (Staging), which takes account of its evolution. This classification takes 
into account three parameters: the size of the original tumor (T), the 
involvement of the regional lymphonodes adjacent to the tumor (N) and the 
presence of metastases at distance (M).  
Depending on the size of the original tumor has the classification  
 T0: no evidence of the original tumor.  
 T1: tumor up to 2 cm in the maximum size.  
 T2: tumor comprised between 2 cm and 5 cm in the maximum size. 
 T3: tumor more than 5 cm in the maximum size.  
 T4: tumor of any size with direct extension to the chest wall and/or to 
the skin. 




As regards the lymph nodes, you define N0 a condition in which the 
regional lymph nodes are not affected, and with a growing abbreviation N1 to 
N3 the progressive involvement of a large number of lymph node stations: 
 N0: regional lymph nodes free of metastases.  
 N1: metastases in axillary lymph nodes ipsilateral mobile.  
 N2: metastases in axillary lymph nodes ipsilateral fixed. 
 N3: metastases in lymph nodes subclavean or supraclavicular 
ipsilateral. 
The presence of metastases at distance is openly by the indication M1, while 
M0 indicates their absence.
(136) 
 
1.8.3 Molecular Classification  
 
The biological characterization and molecular of carcinoma of the 
breast has offered in the last years innovative elements as regards aspects of 
prognosis and treatment. 
The application of molecular biology methods has made it possible to 
classify the breast carcinomas in five different subtypes, depending upon the 
expression by the cancer cells, of specific receptors: 
 Luminal carcinomas: neoplasms characterized by the expression of 
Estrogen receptors (ER) and progesterone (PR), the absence of 
overexpression of the receptor HER2/neu and low proliferative index 
(reduced expression of the antigen Ki67). 
 Luminal carcinomas B (HER2 negative): neoplasms characterized by 
the expression of hormone receptors, absence of overexpression of the 
receptor HER2/neu and intense proliferative activity (high expression 
of the antigen Ki67). 




 Luminal carcinomas B (HER2 positive): neoplasms characterized by 
the expression of hormone receptors and by the overexpression of the 
receptor HER2/neu. 
 Carcinomas HER2 positive (not luminal): neoplasms which 
overexpress the receptor HER2/neu and that do not express the 
hormone receptors. 
 Carcinomas Basal-like: neoplasms characterized by failure of 







Taking into account the fact that the mammary carcinoma can arise in 
different forms, the personalisation of therapy represents the biggest challenge 
. The choice of treatment must in fact take account of several factors which 
considerably influence the response to therapy, such as histological features, 
the molecular characteristics and the staging of the tumor. The main 
therapeutic strategies consist in loco-regional treatments, such as surgery and 
radiotherapy, and in systemic treatments of pharmacological type, such as 





In the field of surgery are distinguished destruction Surgery and 
conservative surgery. The destruction surgery comprises: 
 Radical Mastectomy: removal in the block of the breast and of the 
pectoral muscles greater and lesser with complete axillary dissection. 




 Modified radical mastectomy: preservation of the great pectoral muscle 
or both the pectoral muscles. 
 Simple Mastectomy: removal of the entire breast with the areola 
complex-nipple, preserving the pectoral muscles and the axillary 
lymph nodes. 
 Subcutaneous Mastectomy: removal of the mammary gland, preserving 
the areola and the nipple. 
 
The interventions of conservative surgery include: 
 Removal of tumor nodule with a small portion of mammary tissue 
surrounding healthy. 





1.8.4.2 Radiotherapy  
 
Radiation therapy is a therapeutic strategy that consists in the use of 
radiation at high energy to destroy neoplastic cells and prevent its growth. The 
main purpose of the preoperative radiotherapy is to reduce the volume of the 
tumor and to prevent the seepage into the surrounding structures. In this way 
the radiotherapy may make operable injury otherwise unresectable not or may 
allow the surgeon to put in place measures less destructive. The postoperative 
radiotherapy, or adjuvant, is adopted instead after treatments of conservative 









1.8.4.3 Chemotherapy  
 
For treatment of tumors of the breast are available different 
chemotherapeutic drugs to be administered alone or in combination (poly-
chemotherapy).  
 Anthracyclines (doxorubicin and epirubicin): anticancer drugs 
belonging to the category of antibiotics cytotoxic. Their antineoplastic 
action is due to their intercalation between the nitrogenous bases of 
DNA and to the inhibition of topoisomerase type II. These mechanisms 
bring instability and DNA damage with consequent induction of the 
apoptotic process. 
 Taxanes (Paclitaxel and Docetaxel): drugs that exert their anti-
neoplastic action going to stabilize microtubules, upon binding with 
the subunits of β-tubulin, and preventing depolymerisation. The 
alteration of the dynamic equilibrium tubulin-microtubules is 
responsible for an altered functionality of the mitotic spindle, causing 
the block of cellular division. 
 5-Fluorouracil: drug belonging to the class of antimetabolites 
analogues of pyrimidines. The antineoplastic effect is due to a 
threefold mechanism of action. The fluorodeoxyuridine 
monophosphate (FdUMP), the ribonucleotide which is generated by 
enzymatic route from this analog of the uracil, inhibits thymidylate 
synthase, enzyme responsible for the synthesis of thymidine, 
interfering with the synthesis of DNA. In addition, the fluorouracil 
inhibits the enzyme uracil phosphatase by preventing the use of the 
uracil in RNA synthesis and, lastly, is incorporated, for a small 
fraction, in the RNA, producing an abnormal RNA. 
 




 Methotrexate: drug that inhibits competitively reversible and the 
dihydrofolate reductase (DHFR), an enzyme which participates in the 
synthesis of the tetrahydrofolate, necessary for the synthesis of 
thymidine and purines. The result is the inhibition of the synthesis of 
DNA, RNA and, consequently , of proteins, With alteration of the 
functionality and cell death. 
 Cyclophosphamide: a pro-drug inactive until the conversion by an 
hepatic oxidase P450-dependent in 4-idrossiciclofosfamide. The 
antineoplastic effect is due to the capacity alkylating agent of this 
active metabolite in respect of the nitrogenous bases of DNA, and in 
particular of guanine. 
 Compounds of platinum (cisplatin, carboplatin): drugs capable of 
binding to the nitrogenous bases of nucleic acids, thus causing the 
formation of crosslinks (cross-link) between the two strands 
constituting the double helix of DNA. The result of this mechanism of 
action and the alteration of the structure of DNA and the loss of its 
functions, accompanied by the induction of apoptosis. 
 
Combinations most commonly used in multi-drug chemotherapy 
clinical practice are: AC (doxorubicin and cyclophosphamide), CMF 
(cyclophosphamide, methotrexate and 5-fluorouracil), FEC (5-fluorouracil, 
epirubicin and cyclophosphamide), ACMF (doxorubicin and follow 
cyclophosphamide, methotrexate and 5- fluorouracil), and-CMF (epirubicin 
and follow cyclophosphamide, methotrexate and 5-fluorouracil), AT-CMF 
(doxorubicin/paclitaxel and follow cyclophosphamide, methotrexate and 5-
fluorouracil), AC- paclitaxel or docetaxel (doxorubicin and cyclophosphamide 
and follow paclitaxel or docetaxel). 
 




The side effects of chemotherapy depend on the fact that the cytotoxic 
action of these antineoplastic agents is not limited to cancer cells but also 
extends to healthy cells of tissues in active proliferation, such as cells of the 
oral mucosa and the intestinal cells of the bladder, embryonic cells and bone 
marrow precursors. The main side effects that occur during chemotherapy are 
nausea, vomiting, stomatitis, gastrointestinal disorders, alopecia and 




1.8.4.4 Hormonal therapy  
 
The hormonal therapy is indicated for patients with tumors hormone-
responsive (ER+/PR+). It is based on pharmacological treatments adapted to 
interfere with the mechanisms that lead estrogens to stimulate the proliferation 
of cancer cells. The choice of the type of treatment to be adopted, in addition 
to the degree of progress of the disease depends on the fact that the woman is 
already entered or less in menopause. In women before menopause most of 
female sex hormones circulating is released into the blood by the ovaries. 
While in women after the menopause the ovaries no longer produce hormones, 
and estrogens circulating are produced by peripheral tissues of the organism 
(especially the adipose tissue, muscles and skin) starting from the androgens 
produced by the adrenal glands. The hormonal therapy can lead to various side 
effects, but smaller than those induced by chemotherapy fever, including: hot 
flushes and sweats, tiredness, articular pains, nausea, weight increase and 
"tumor flare", temporary exacerbation of the disease which may occur in less 
than a case on one hundred, in the early stages of care.  
The main classes of drugs used in the hormonal therapy are represented 
by: Selective Estrogen Receptor Modulators or SERMS (selective estrogen  




receptor modulator). This is drugs that act on the estrogen receptors exerting, 
depending on the fabric, a different activities and ensuring the ability to act as 
an agonist on certain functions or fabrics and as an antagonist on others. 
Belongs to this class tamoxifen, drug indicated in women in pre-menopausal 
women. Tamoxifen is a competitive antagonist of the receptor ER, which 
interrupts the stimulus to the proliferation of the cells by estrogens . Analogues 
of LHRH. Belonging to this class are the goserelin and tryptoreline , drugs that 
can be administered alone or in association with tamoxifen. Are indicated for 
women premenopausal, able to act more upstream of the other hormonal drugs 
because they block the production of the luteinizing hormone (LH), with 
which the pituitary stimulates tasks of the ovaries. Inhibitors of aromatase: to 
this class of drugs belong various substances, including anastrazole, 
exemestane and letrozole, capable of blocking the action of the aromatase 
enzyme, essential for estrogen synthesis starting from the androgens, produced 
by the adrenal cortex also in women. 
 
1.8.4.5 Immunotherapy  
 
Immunotherapy is a therapeutic approach that is based on the use of 
monoclonal antibodies directed against specific molecular targets and 
represents a pharmacological therapy targeted target (therapy) which allows to 
limit the side effects of chemotherapy fever. For the treatment of mammary 









1.9 Prostate cancer 
 
Prostate cancer is a malignant disease characterized by the uncontrolled 
proliferation gland cells, generating adenocarcinomas. 
In addition to the adenocarcinoma, in the prostate can be also found sarcomas, 






Prostate cancer is one of the more common tumors in the male 
population. It represents about 15% of all cancers diagnosed in man: in 2012, 
about 36.300 new cases were diagnosticated in Italy..
(140)
 
One of the main risk factors for prostate cancer is the age: the 
possibility of becoming ill are very scarce before 40 years, but significantly 
increase after 50 years.Aabout two tumors on three are diagnosed in people 
with more than 65 years. Researchers have demonstrated that many (between 
70% and 90%) men over 80 years have a cancer of the prostate, although in 
most cases the disease does not give signs.  
Familiarity is another factor not to be overlooked. In fact, the risk of 
illness is double if there have any case in family. Also mutations in BRCA1 
and BRCA2 genes, already involved in promoting the onset of tumors of the 
breast and ovary, or gene HPC1, can increase the risk of developing prostate 
cancer. The probability of illness could be also linked to high levels of 
hormones such as testosterone, which promotes the growth of prostatic cells, 
and hormone IGF1, similar to the insulin, but who works on the growth of 
cells and not on the metabolism of sugars. 
 
 






Prostate cancer is classified by the grade of aggressiveness of the 
disease and the stadium, which indicates the status of the disease. Depending 
on the stage of the disease it is also proceeds to carry out examinations of 
staging as CT (Computed tomography or magnetic resonance. To check for 
the presence of any metastases to the skeleton often uses the bone 
scintigraphy. The pathologist that analyses the removed tissue with the biopsy 
assigns to the tumor the so-called degree of Gleason, i.e. a number between 1 
and 5 that indicates how far the aspect of tumor glands is similar or different 
from that of normal glands. 
More like are, the lower the degree of Gleason. Tumors with a degree 
of Gleason less than or equal to 6 are considered to be of low degree, those 
with 7 of intermediate degree, while those between 8 and 10 high-grade. 
To define instead the stage to the tumor is typically use the TNM 




Today there are many types of treatment for prostate cancer each of 
which presents the benefits and side effects specific. Only a careful analysis of 
the characteristics of the patient (age, life expectancy etc.) and of the disease 
(low, intermediate or high risk) will allow the specialist urologist will 
recommend the best strategy and custom and agreeing the therapy also 
according to the preferences of those who must be subject to treatment.
(141)
 
In some cases, the treatment of cancer is called “wait” therapy. The 
Anglo-Saxons call watchful waiting, a "watchful waiting" that does not 
provide treatments, but only checks rather frequent (PSA, rectal exam, biopsy)  




that allow you to control the evolution of the disease and to check for changes 
that deserve an intervention. This approach is used especially for elderly 
patients or man with other serious illnesses, or in the case of tumors of small 
dimensions and with low risk (micro outbreak in biopsy. 
The active therapy, instead, often is a radical surgery. The radical 
prostatectomy - removal of the entire prostate gland and lymphonodes of the 
region close to the tumor. It is considered a curative intervention, if the disease 
is confined in the prostate. Thanks to the considerable improvements of 
surgical instruments, today the operation for the removal of the prostate can be 
carried out in a classic way (radical prostatectomy pubic back open), 
laparoscopically, or via laparoscopy robot-assisted. 
For tumors in advanced stages, the scalpel alone is often unable to cure 
the illness and there is therefore the need to associate treatments such as 
radiotherapy or hormonal therapy. For the treatment of prostate cancer, 
treatments considered standard, it has been demonstrated that the radiotherapy 
external beam is effective in tumors of low risk, with results similar to those of 
the radical prostatectomy. Another radiotherapy technique that seems to offer 
similar results to previous in diseases of low risk is the brachytherapy, which 
consists in the insert in the prostate small "seeds" issuing radiation. 
When prostate cancer is located in metastatic stage, unlike what 
happens in other tumors, chemotherapy is not the treatment of first choice and 
you prefer to hormonal therapy. This has the purpose of reducing the level of 
testosterone , male hormone that stimulates the growth of the tumor cells of 
the prostate, but brings with it side effects such as drop or annulment of sexual 
desire, impotence, flushing, weight increase, osteoporosis, loss of muscle mass 
and tiredness. Among the local therapies still being reviewed there are the 
cryotherapy (elimination of tumor cells with cold) and HIFU (focused 
ultrasound on tumor). There are also in the phase of experimentation in some  




cases already very advanced, even vaccines which push the immune system to 
react against the tumor and destroy it, and drugs anti-angiogenic that block the 
formation of new blood vessels preventing cancer to receive the nourishment 
necessary to evolve and develop further. 
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2 Chapter II 
 





















2.1.1 Group III metal complexes 
 
Complexes of many metals in the periodic table have been studied up 




Many of the pharmacological properties of the group III metals are due to their 
affinity for Ca
2+
 sites in biological molecules and to the formation of a 







in the biological processes.
 (1, 2)
 
The lanthanides can replace calcium in the protein, and so calcium dependent 
enzymes can be inhibited or be activated by lanthanides. It has been proposed 
that the stimulation or the inhibitory effect of the lanthanides may be a 
function of role of calcium in the native enzyme. If calcium plays a catalytic 
role, its substitution with a group III ion leads to the deactivation of the 
enzyme and the degree of inhibition depends on the ionic radius of metal. 
Instead, if calcium plays a structural role, the replacement with a M
3+
 ion 
gives, at least, the maintenance of the activity. 
(1, 2)
 
Accordingly, the mode of action of anticancer-active group III metals is 
related to their possible inhibition of ion function that is essential for cells 
cycle regulation and antitumor activity and significantly enhanced by 
complexation with various ligands. 
In fact, lanthanide complexes with coumarins exhibited superior activity in 
various tumor models as compared to the corresponding inorganic salts. 
Coumarins are an important group of organic compounds that shows a wide 








Complexes of rare earth metal as cerium(III), lanthanum(III) and 




Rogers and coworkers reported the cytotoxic activity of acenocumarol 
samarium(III) and gadolinium(III) complexes against melanoma B16 and 
fibrosarcoma L929 cell lines.
 (8)
 
Lanthanide complexes are the texaphyrins (figure 2.1), having macrocyclic 
monoanionic ligands containing five coordinating nitrogen atoms in the central 
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Figure 2.1. Structures of texaphyrins complexes 
 
Furthermore, it has been reported that a series of cerium(III) complexes 
with bipyridyl or phenanthroline ligands showed an interesting  




antiproliferative activity against tumoral cell lines (figure 2.2). Recently, the 
lanthanum complex of phenanthroline derivative (KP772) has shown to exert 
comparable activity to that of cis-platin and methotrexate against a wide range 




Recently, it has been evaluated the cytotoxic activity of a significant 
number of new complexes of metals of group III and lanthanides with 
heterocyclic ligands,
(13-19)
 and some of us have reported the synthesis and 
characterization of scandium(III), yttrium(III) and some lanthanide (III) 
complexes stabilized by tri-dentate monoanionic ligands which gave 
remarkable activity, and in some case were significantly more active than cis-










41M CH1 SKBr3 SW480 
1.5 ± 0.2 1.2 ± 0.2 2.6 ± 0.4 2.7 ± 0.3 
 
Figure 2.2. Cytotoxicity of KP776 in Four Human Cancer Cell Lines. As determined 
by the MTT Assay Using 96-h Exposure.  

































Figure 2.3. Structures of scandium(III), yttrium(III) and some lanthanide (III) 
complexes stabilized by tri-dentate monoanionic ligands 
 
Recently, some of us have reported the synthesis and characterization 
of scandium(III), yttrium(III), samarium(III) and neodymium(III) chloro- or 
triflate-complexes with tridentate monoanionic quinoline-phenoxy-amine, 
quinoline-phenoxy-imine and ansa-monocyclopentadienyl-imino-pyridine 
ancillary ligands, and evaluated their cytotoxic activity on rat glioma (C6), 




Moreover, we reported the synthesis and characterization of a series of 
group III and lanthanide [N,N,N]-heteroscorpionate complexes with Ƞ
3
-NNN-
coordination of the heteroscorpionate ligand N,N'-dicyclohexyl-2,2-bis-(3,5-
dimethyl-pyrazol-1-yl)-acetamidinate (cybpamd), detailing on cytotoxic 
screening and further investigation of [Ln(OTf)2(cybpamd)(THF)] {where Ln 
= Sc (2), Y (3), La (4), Nd (5), Sm (6), Dy (7), Yb (8); OTf = SO3CF3}.  
 




Structures of these complexes are shown in figure 2.4. The complexes were 
tested on human epithelial lung adenocarcinoma (A549), human melanoma 
(A375), human epithelial cervix adenocarcinoma (HeLa), human embryonic 
kidney (HEK-293) and murine macrophage (J774.A1) cell lines. On murine 
macrophage (J774.A1) cell line all tested complexes, except that of scandium 
that shows a reasonable activity. On human epithelial cervix adenocarcinoma 
(HeLa) complexes 3, 5 and 6 are significantly more active than cis-platinum, 
as well as complex 5 is more active on human embryonic kidney (HEK-293) 
cell line.  
The continuing involvement of groups looking for absolute 
qualification in the field of the study of new potential anticancer agents 
suggests that it will be possible to further evaluate the potential of molecules 
already synthesized, as well as those that we are going to prepare, even on 
other cancer cell lines. Moreover, the study of the mechanism of action of 
these molecules provides valid indications also on the structural characteristics 
that these molecules must possess in order to best carry out their anticancer 
action. This will also suggest to the group that will be interested in the 
synthesis, the design and the development of new molecules to meet best the 













Figure 2.4. Structures of lanthanide [N,N,N]-heteroscorpionate complexes with Ƞ
3
-
NNN-coordination of the heteroscorpionate ligand N,N'-dicyclohexyl-2,2-bis-(3,5-
dimethyl-pyrazol-1-yl)-acetamidinate (cybpamd) 
 
Hence, the capability of this compound to elicit relevant repressive 
effects on cancer cell growth could be taken into account towards novel 
pharmacological approaches in cancer therapy. Further experiments are 
needed to clarify the molecular mechanisms involved in the growth responses 
of the compound tested as well as to evaluate it in vivo chemotherapeutic 
potential. 
  




2.2 Aims of the project 
 
The aim of this study was the synthesis and the characterization of 
ligands and related metal complexes by nuclear magnetic resonance (NMR) to 
evaluated their potential antitumor activity.  
Starting from the literature, we synthesized new compounds with 
structural changes, adapted to investigate the role of the metal centre and of 
the substituents for antitumor activity. We proceeded on two fronts: 
modification of the metal centre and changes on the ligands. 
Firstly group III metal complexes stabilized from cyclopentadienyl 
ligands were synthesized. The selected cp-ligands were yet able to stabilize the 
titanium cation by intramolecular or intermolecular coordination. Compounds 
were tested as anticancer agents, in particular for the topical application for the 
treatment of solid tumors, yet non-treatable, such as breast cancer triple 
negative (TN) and prostate cancer.  
Hence, the stabilization of lanthanides with heterocyclic ligands having 
more than one donor atom was of great interest in the chemistry of 
coordination compounds as well as it can lead to compounds with noteworthy 
cytotoxic effects. 
Thus, given the activities of many interesting complexes of group III 
with chelating ligands, we synthesized and tested on selected tumor cell lines, 
a series of complexes having the same ligands that used in the synthesis of 
titanium complexes. In fact, titanium and metals of group III should have 
different mechanisms of action and this could allow to have completely 
different specificity and selectivity of the two groups of complexes. 
An interesting aspect that we intended to study,was related to 
significant differences in atomic radius and electronegativity for group III and 
rare earth metals, because it could provide some interesting specificity for  




obtained compounds. In fact, these two parameters make it possible to achieve 
a wide variety of complexes with ligands capable of stabilize the metal ion by 
a coordination more or less strong, either acting as bidentate that as 
monodentate ligands. The latter type of coordination could make available a 
substituent still able to give additional interactions with target molecules.  
 
2.2.1 Evaluation of the drug-membrane interactions 
 
In the present study, the interaction of the antitumor agents CAM-2 and 
CAM-7 with biological membranes was investigated by using liposomes as 
cell membrane mimetic models.  
The interaction of drugs with biological membranes, indeed, plays a 
key role in their pharmacological effects, since the site of action is often 
embedded within membranes
(21)
 which act as physiological barriers in the 
absorption and distribution processes of therapeutic agents in the organism.  
The drug’s ability to interact with the membrane depends on its 
lipophilicity which influences the pharmacokinetic and pharmacodynamics 
profiles and can be correlated with the therapeutic and/or toxic effects. 
(22)
 
In the aim to evaluate the drug’s hydrophilic/lipophilic equilibrium, a 
partition coefficient (Kp) between aqueous and lipid phases, which represents 
a significant parameter affecting the in vivo action of anticancer drugs, was 
determined by UV-Vis spectrophotometry employing liposomes made of egg 
phosphatidylcholine (EPC) as cell membrane mimetic models. Liposomes 
present, indeed, a membrane structure similar to the cellular one and EPC was 
chosen because natural plasma membranes contain a high amount of 
phosphatidylcholines. 
(23, 24)  




2.3 Materials and Methods. 
 
2.3.1 General procedure 
 
All manipulations were carried out under oxygen- and moisture-free 





All the solvents were thoroughly deoxygenated and dehydrated under argon by 
refluxing over suitable drying agents, while NMR deuterated solvents (Euriso-




All chemicals were obtained from Aldrich chemical Co. and used 
without further purification. Cyclopentadiene was obtained by freshly cracked 
dicyclopentadiene.  
 
2.3.4 Characterization techniques 
 
1




H COSY and 
13
C NMR spectra 
were recorded on Bruker Avance 250 Spectrometer operating at 250 MHz (
1
H) 
and 62,5 MHz (
13
C), on Bruker Avance 300 Spectrometer operating at 300 
MHz (
1
H) and 75 MHz (
13
C) and on a Bruker Avance 400 Spectrometer 
operating at 400 MHz (
1
H) and 100 MHz (
13
C). Chemical shifts referred to 
tetramethylsilane used as internal standard. 




2.3.5 Cell lines 
 
MDA.MB213-tumor cell line of human breast acquired from the ATCC 
(American Tissue Cell Cultures - ATCC® HTB-26™), triple negative for ER 
receptor.  
DU145-human cell line of prostate tumor acquired from the ATCC 
(American Tissue Cell Cultures - ATCC® HTB-81™). 
B16F10- tumor cell line of melanoma acquired from the ATCC 
(American Tissue Cell Cultures - ATCC® CRL-6475™) 
 
2.3.6 Biological assay kit 
 
MTT Cell Proliferation Assay Kit - purchased from TREVIGEN - 
Catalog # 4890-025-K. 
 
2.3.7 Evaluation of the drug membrane interaction 
 
 2.3.7.1 Materials 
 
Egg phosphatidylcholine (EPC) was obtained from Sigma (St. Louis, 
MO) and used as received.  
Solutions were prepared with HEPES buffer (10 mM, I = 0.1 M, pH 7.4). The 
ionic strength was adjusted with NaCl. All solvents were reagent grade or 
HPLC-grade and provided by Carlo Erba reagents (Milan, Italy). 
 
 




2.3.7.2 Liposomes preparation 
 
Liposomes were prepared according to the thin film hydration method. 
(25) 
A solution of lipid (EPC) in chloroform was evaporated to dryness 
under a nitrogen stream. The resultant lipid film, in an amount that would 
provide a final lipid concentration of around 2 mM, was then left under 
vacuum overnight to remove all traces of the organic solvent. The resultant 
dried lipid film was hydrated with HEPES buffer and vortexed at room 
temperature in order to obtain multilamellar vesicles (MLVs). Lipid 
suspensions were equilibrated at 25°C for 30 min and further extruded 10 
times through polycarbonate filters (Nucleopore, Pleasanton, CA) with a pore 
size of 100 nm, to form large unilamellar vesicles (LUVs, stock solution).  
 
2.3.7.3. Determination of partition coefficient (Kp) by UV-Vis 
spectrophotometry 
 
The partition coefficient (Kp) of CAM-2 and CAM-7 between 
liposomes and an aqueous phase was determined by UV-Vis 
spectrophotometry.  
The EPC stock suspension was diluted to prepare a HEPES buffered 
LUVs suspension (EPC concentration 1000 μM) and contained a fixed 
concentration of drug (40 μM). The corresponding reference solution was 
prepared in the same conditions but in the absence of drug. All suspensions 
were incubated at 25°C in the dark for 2 h to allow drug partition equilibrium 
to be established. Then, the samples were placed in diafiltration tubes 
(Vivaspin 20 centrifugal concentrator, MWCO 3,000 Da) and centrifuged. The  




UV-Vis absorption spectra of the aqueous phases were recorded with a Jasco 
V-530 UV/Vis spectrometer.  
The corrected absorption spectra were obtained by subtracting each 
reference spectrum from the correspondent sample spectrum in order to 
eliminate the spectral interferences due to the light scattered by lipid vesicles.  
Partition coefficients were then calculated by the following Equation 
(1):  
   
  
  
               (1) 
 
where nm and nw are the number of drug moles distributed on the lipid 
membrane phase and in the aqueous phase, respectively, while Kp is the 
partition coefficient. 
 
2.3.8 Distillation of Cylopentadiene. 
 
We make all the manipulation in nitrogen atmosphere. We prepare a 
250 ml three-necked flask, on which we mounted a dropping funnel and a 
reflux condenser. On the consenser we put a head of Claisen, refreshed by 
current water and connected with a tailed tube where we collect the 
cylopentadiene distillate. We put the reaction flask in a heating hood on a plate 
of stirring. We put dicyclopentadiene in the dropping funnel and decalin in the 
reaction flask. As soon as the decalin begins to boil, reaching a temperature of 
180°C, we leave dropping the dicyclopentadiene in the flask. At 180°C 
dicyclopentadiene turns in the monomer (undergoes back Diels-Alder). The 
monomer vapours converge in the head of Claisen and condensed into a 
collection tube cooled.  





H NMR (300 MHz, CDCl3): 3.00(t, 2H, C5H6,); 6.48(m, 2H, C5H6); 
6.59(m, 2H, C5H6). 
 
2.3.9 Synthesis of ligands 
 
2.3.9.1 Synthesis of 6-phenylfulvene 
 
The synthesis was carried out under nitrogen atmosphere. We added 3 
ml of pyrrolidine to a solution of 5 ml of cyclopentadiene and 2,4 ml of 
benzaldehyde in 25 ml of dry methanol. After about 20 minutes from the 
addition, the color of the solution slowly turned from colorless to dark red. 
After 4,5 hours we followed the reaction by TLC., using pentane as eluent. 
When the TLC showed only one spot, we interrupted the reaction by adding 
1.8 ml of acetic acid. The reaction mixture was, then, diluted with 20 ml of a 
mixture of diethyl ether and water (1:1). The resultant organic layer was 
separated and washed with 50 ml of diethyl ether for 3 times. We washed the 
combined organic extracts with a satured aqueous NaCl solution. The organic 
solution was dried over Na2SO4. 
1
H NMR (300 MHz, CDCl3): 6.70, 6.52, 6.36, 6.33 (m, 4H, C5H4,); 
7.61-7.59-7.43-7.40-7.36 (m, 5H, C6H5); 7.24 (s, 1H, Ph-CH-Cp). 
 
2.3.9.2 Synthesis of 4-methoxy-phenylfulvene 
 
The reaction was carried out in inert nitrogen atmosphere. We mixed 
30 ml of anhydrous methanol, 4.1 ml of cyclopentadiene and 2.4 ml of 4-
methoxybenzaldehyde in a tailed flask. The reaction started after the addiction  
 




of 2,5 ml of pyrrolidine. The colour of the solution turned immediately from 
transparent to red-orange. After about 20 minutes, we saw the formation of a 
red precipitate. We followed the reaction by TLC. We used as eluent a mixture 
of ethyl acetate and dichloromethane (7:3). When the TLC showed only one 
spot, we interrupted the reaction by adding 1.8 ml of acetic acid. We proceed 
to extraction, adding 10 ml of ethyl ether and 10 ml of distilled water, 
transferring the mixture in a separating funnel to separate the two phases. We 
washed the aqueous phase with 30 ml of ethyl ether for 3 times. We pooled 
and washed the organic phases with a concentrated solution of NaCl. We 
treated the organic phase with anhydrous Na2SO4 and finally, we filtered and 
dried it. 
 1
H NMR (300 MHz, CDCl3): 6.70-6.64-6.45-6.30 (m, 4H, C5H4,); 
7.53-7.50-6.71-6.88-6.85 (m, 4H, C6H4,); 3.75 (s, 3H, OCH3,); 7.10 (s, 1H, 
Ph-CH-Cp). 
 
2.3.9.3 Synthesis of 6-(3’,4’-dimethoxyphenyl)fulvene 
 
The synthesis was carried out in inert nitrogen atmosphere. We added 
2,5 ml of pyrrolidine to a solution of 5 ml of cyclopentadiene and 2 g of 3,4-
dimetoxy-benzaldehyde in 30 ml of anhydrous methanol. The color of the 
solution turned immediately from transparent to red-orange. After 20 hours a 
solid precipitated out the solution and acetic acid (1.8 ml) was added. We 
proceed to extraction, adding 10 ml of dichlorometane and 10 ml of distilled 
water, transferring the mixture in a separating funnel to separate the two 
phases. We washed the aqueous phase with 30 ml of dichloromethane for 3 
times. We pooled and washed the organic phases with a concentrated solution 
of NaCl. We treated the organic phase is with anhydrous Na2SO4 and finally, 
we filtered and dried it. 





H NMR (300 MHz, CDCl3): 6.73-6.69-6.50-6.34 (m, 4H, C5H4); 
6.93-6.90-6.79 (m, 3H, C6H3,); 3.94 (s, 6H, OCH3); 7.19 (s, 1H, Ph-CH-Cp). 
 
2.3.9.4 Synthesis of 6-(2’,4’-dimethoxyphenyl)fulvene 
 
The reaction was carried out in inert nitrogen atmosphere. We mixed 
50 ml of anhydrous methanol, 5 ml of cyclopentadiene and 2 g 2,4-dimethoxy-
benzaldehyde in a tailed flask. The reaction started after the addiction of 2,5 
ml of pyrrolidine. The color of the solution turned immediately from 
transparent to red-orange. We refluxed the mixture for about 20 hours  and 
then we interrupted the reaction by adding 1.8 ml of acetic acid. We proceed to 
extraction, adding 40 ml of dichloromethane and 40 ml of distilled water, 
transferring the mixture in a separating funnel to separate the two phases. We 
washed the aqueous phase with 50 ml of dichloromethane for 3 times. The 
combined organic phases were washed with a concentrated solution of NaCl. 
We dried the organic phase with anhydrous Na2SO4 and finally, we filtered 
and removed the solvent. 
1
H NMR (300 MHz, CDCl3): 6.68-6.63-6.48-6.29 (m, 4H, C5H4), 
7.63-7.61-7.52 (m, 3H, C6H3), 3.87 (s, 6H, OCH3), 6.65(s, 1H, Ph-CH-Cp). 
 
2.3.9.5 Synthesis of 6-(3’,5’-dimethoxyphenyl)fulvene 
 
The synthesis was carried out in inert nitrogen atmosphere. We added 
2,5 ml of pyrrolidine to a solution of 5 ml of cyclopentadiene and 2 g of 3,5-
dimetoxy-benzaldehyde in 100 ml of dry methanol. The colour of the solution 
turned immediately from colourless to red. After 20 hours a solid precipitated 
out the solution and acetic acid (1.8 ml) was added. We proceed to extraction,  
 




adding 10 ml of dichloromethane and 10 ml of distilled water, transferring the 
mixture in a separating funnel to separate the two phases. We washed the 
aqueous phase with 50 ml of dichloromethane for 3 times. We pooled and 
washed the organic phases with a concentrated solution of NaCl. We treated 
the organic phase is with anhydrous Na2SO4 and finally, we filtered and dried 
it. 
1
H NMR (300 MHz, CDCl3): 6.73-6.69-6.50-6.34 (m, 4H, C5H4, m), 
6.93-6.90-6.79 (m. 3H. C6H3), 3.94 (s, 6H, OCH3,); 7.19 (s, 1H, Ph-CH-Cp ). 
 
2.3.10 Synthesis of lithium salt 
 
2.3.10.1 Reduction of 4-methoxy-phenylfulvene. 
 
In inert atmosphere we picked up 6.5 ml of a solution of super-hydride 
and we transferred it to a 250 ml tailed flask. We removed the solvent (THF) 
to obtain a white solid and we dissolved it in 70 ml of anhydrous diethyl ether. 
We dissolved 1.0 g of 4-methoxyphenyl-fulvene in 30 ml of anhydrous diethyl 
ether and added it to the solution of the reductant. We left the reaction under a 
stream of nitrogen at room temperature, for one night until the formation of a 
suspension. In the morning we transferred the reaction mixture in a tailed tube 
where the lithium salt precipitated. We removed the solvent by siphoning and 
we washed the precipitate with 50 ml of anhydrous diethyl ether for three 
times. Finally, we dried and weighed the salt. 
1
H-NMR (400 MHz, DMSO): 3.30 (s, 2H, Ph-CH2-Cp), 3,67 (s, 3H, 
OCH3), 5.13-5.14-5.15-5.16 (m, 4H, C5H4), 6.68-6.71-7.07-7.10 (d, 4H, 
C6H4). 
 




2.3.10.2 Reduction of 6-(3’,4’-dimethoxyphenyl)fulvene 
 
In inert atmosphere we picked up 6.5 ml of a solution of super-hydride 
and we transferred it to a tailed flask 250 ml. We removed the solvent (THF) 
to obtain a white solid and we dissolved it in 70 ml of dry diethyl ether. We 
dissolved 1.0 g of 6-(3’,4’-dimethoxyphenyl)fulvene in 30 ml of dry diethyl 
ether and added it to the solution of the reductant. We left the reaction under a 
stream of nitrogen at room temperature, for one night until the formation of a 
suspension. On the morning we transferred the reaction mixture in a tailed 
tube where the lithium salt precipitated. We removed the solvent by siphoning 
and we washed the precipitate with 50 ml of anhydrous diethyl ether for three 
times. Finally, we dried and weighed the salt. 
1
H-NMR (300 MHz, CDCl3): 3.63 (s, 2H, Ph-CH2-Cp), 3.68 (s, 6H, 
OCH3), 5.15 (s, 4H, C5H4), 6.70-6.81 (dd, 4H, C6H4). 
 
2.3.11 Synthesis of yttrium cyclopentadienyl complexes 
 
2.3.11.1 Synthesis of complexes [C5H4–CH2–C6H4–OCH3]YCl2 [(4-
methoxybenzyl)cyclopentadienyl]-yttrium-dichloride. (CAM 1) 
 
We weighed in dry-box, in two separate balls, 200 mg of salt of lithium 
4-methoxybenzyl-ciclopentedienile and 202 mg of YCl3. We dissolved the 
ligand in 8 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 32 ml dry THF and transferred it to 
the reaction flask. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the ligand in the solution containing the metal 
halide. We left it on stirring overnight and climbing slowly to room  
 




temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 42% 
1
H-NMR (300 MHz, DMSO): 2.86 (s, 2H, CH2), 3.33 (s, 3H, OCH3), 
5.99 (d, 1H, C5H4), 6.09 (s, 1H, C5H4), 6.24 (d, 1H, C5H4), 6.38 (m, 1H, 
C5H4), 6.84 (m, 2H, C6H4), 7.05 (m, 2H, C6H4). 
13
C-NMR (300 MHz, DMSO): 54.97 (s, 1C, OCH3), 41.78 (s, 1C, 
CH2), 113.74-126.83-127.14-129.49-131.19-132.21-132.68-134-134.45-
146.65-157.51 (s, 11C, C5H4/C6H4). 
 
2.3.11.2 Synthesis of complex [Cp-CH2-C6H5-OCH3]2YCl Bis-[(4-
Methoxybenzyl)cyclopentadienyl]-yttrium-chloride.(CAM 2) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 4-
methoxybenzyl-ciclopentedienile and 80 mg of YCl3. We dissolved the ligand 
with 50 ml of dry THF and moved the solution into the reaction flask. We 
solubilized the metal halide in 11 ml dry THF and transferred it to the 
dropping funnel. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the metal in the solution containing the ligands. We 
left it on stirring overnight and climbing slowly to room temperature. We 
removed the solvent and we dissolved the resulting solid product in 40 ml of 
anhydrous dichloromethane, We filtered the mixture through celite to remove 
lithium chloride. We dried the complex and we carried it in dry box to recover 
and to weight it. The product was characterized by NMR analysis proton. 
Yield: 21% 





H NMR (300 MHz, DMSO): 2.87 (d, 4H, CH2), 3.60 (s, 4H, CH2), 
3.71 (s, 6H, OCH3), 5.99 (s, 2H, C5H4), 6.09 (s, 2H, C5H4), 6.21 (s, 2H, C5H4), 
6.38 (s, 2H, C5H4), 6.84 (m, 4H, C6H4), 7.10 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 54.30 (s, 2C, OCH3), 40.87 (s, 2C, 
CH2), 113.11-125.78-125.97-129.34-130.40-131.12-131.68-133.67-134.02-
145.56-156.15 (s, 22C, C5H4/C6H4). 
 
2.3.11.3 Synthesis of [C5H4–CH2–C6H3(OCH3)2]YCl2 [(3,4-dimethoxybenzyl)-
cyclopentadienyl]-yttrium-dichloride. (CAM 5) 
 
We weighed in dry-box, in two separate balls, 200 mg of salt of lithium 
3,4-dimethoxybenzyl-ciclopentedienile and 176 mg of YCl3. We dissolved the 
ligand in 8 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 32 ml dry THF and transferred it to 
the reaction flask. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the ligand in the solution containing the metal 
halide. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 46% 
1
H-NMR (300 MHz, CDCl3): 2.87 (s, 2H, CH2), 3.70 (s, 6H, OCH3), 
6.01 (s, 1H, C5H4), 6.11 (s, 1H, C5H4), 6.24 (s, 1H, C5H4), 6.40 (s, 1H, C5H4), 
6.67–6.86 (m, 3H, C6H3). 
 
 





C-NMR (300 MHz, DMSO): 53.50 (s, 2C, OCH3), 34.7 (s, 1C, CH2), 
110.37-111.45-113.32-118.89-120.78-130.67-135.87-147.54-148.34 (s, 11C, 
C5H4/C6H3). 
 
2.3.11.4 Synthesis of complex [Cp-CH2-C6H5-(OCH3)2]2YCl Bis-[(3,4-
dimethoxybenzyl)-cyclopentadienyl]-yttrium-chloride (CAM 6) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
3,4-dimethoxybenzyl-ciclopentedienile and 66 mg of YCl3. We dissolved the 
ligand with 6 ml of dry THF and moved the solution into the reaction flask. 
We solubilized the metal halide in 11 ml dry THF and transferred it to the 
dropping funnel. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the metal in the solution containing the ligands. We 
left it on stirring overnight and climbing slowly to room temperature. We 
removed the solvent and we dissolved the resulting solid product in 40 ml of 
anhydrous dichloromethane. We filtered the mixture through celite to remove 
lithium chloride. We dried the complex and we carried it in dry box to recover 
and to weight it. The product was characterized by NMR analysis proton. 
Yield: 36% 
1
H NMR (400 MHz, DMSO): 2.87 (d, 4H, CH2), 3.60 (d, 4H, CH2), 
3.70 (s, 12H, OCH3), 5.98 (s, 2H, C5H4), 6.11 (s, 2H, C5H4), 6.23 (s, 2H, 
C5H4), 6.39 (s, 2H, C5H4), 6.86 (m, 4H, C6H4), 7.12 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 54.87 (s, 4C, OCH3), 35.79 (s, 2C, 









2.3.12 Synthesis of scandium cyclopentadienyl complexes 
 
2.3.12.1 Synthesis of complex [Cp-CH2-C6H5-OCH3)]ScCl2 [(4-
methoxybenzyl)cyclopentadienyl]-scandium-dichloride.(CAM 3) 
 
We weighed in dry-box, in two separate balls, 200 mg of salt of lithium 
4-methoxybenzyl-ciclopentedienile and 157 mg of ScCl3. We dissolved the 
ligand with 8 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 32 ml of THF-dry and we 
transferred it to the reaction flask. We immersed the flask in the thermostated 
bath at -78 °C, and then slowly we added the ligand in the solution containing 
the metal halide. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 50 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 95% 
1
H NMR (300 MHz, CDCl3): 2.80 (d, 2H, CH2), 2.92 (d, 2H, CH2), 
3.60 (s, 3H, OCH3), 5.98 (s, 1H, C5H49, 6.09 (s, 1H, C5H4), 6.23 (d, 1H, 
C5H4), 6.37 (m, 1H, C5H4), 6.84 (m, 2H, C6H4), 7.05 (m, 2H, C6H4). 
13
C-NMR (300 MHz, DMSO): 55.79 (s, 1C, OCH3), 42.87 (s, 1C, 
CH2), 113.34-125.65-128.15-129.97-131.65-132.67-132.96-134.56-134.78-









2.3.12.2 Synthesis of complex [Cp-CH2-C6H5-OCH3]2ScCl Bis-[(4-
methoxybenzyl)cyclopentadienyl]-scandium-chloride.(CAM 4) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
4-methoxybenzyl-ciclopentedienile and 59 mg of ScCl3. We dissolved the 
ligand with 8 ml of anhydrous THF and moved the solution in the reaction 
flask. We solubilized the metal halide in 8 ml of THF-dry and we transferred 
into the dropping funnel. We immersed the flask in the thermostated bath at -
78 °C, and then slowly we added the metal in the solution containing the 
ligand. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane, We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton.  
Yield: 24% 
1
H NMR (300 MHz DMSO): 2.86 (s, 4H, CH2), 3.60 (s, 4H, CH2), 
3.71 (s, 6H, OCH3), 5.76 (s, 2H, C5H4), 6.09 (s, 2H, C5H4), 6.23 (d, 2H, C5H4), 
6.38 (s, 2H, C5H4), 7.08 (m, 4H, C6H4), 7.12 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 53.99 (s, 2C, OCH3), 40.12 (s, 2C, 
CH2), 112.95-124.67-125.79-129.38-130.21-130.94-131.33-132.62-133.75-
144.33-155.14 (s, 22C, C5H4/C6H4). 
 
2.3.12.3 Synthesis of complex [C5H4–CH2–C6H4–(OCH3)2]ScCl2 [(3,4-
dimethoxybenzyl)cyclopentadienyl]-scandium-dichloride.(CAM 7) 
 
We weighed in dry-box, in two separate balls, 200 mg of salt of lithium 3,4-
dimethoxybenzyl-ciclopentedienile and 157 mg of ScCl3. We dissolved the  




ligand in 8 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 32 ml dry THF and transferred it to 
the reaction flask. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the ligand in the solution containing the metal 
halide. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 33% 
1
H NMR (300 MHz, CDCl3): 3.44 (s, 2H, CH2), 4.18 (s, 2H, CH2), 
4.39 (s, 6H, OCH3), 6.52 (s, 1H, C5H4), 6.67 (s, 1H, C5H4), 6.80 (s, 1H, C5H4), 
6.94 (s, 1H, C5H4), 7.26 (m, 2H, C6H3), 7.31 (m, 1H, C6H3). 
13
C-NMR (300 MHz, DMSO): 54.80 (s, 2C, OCH3), 33.99 (s, 1C, 
CH2), 110.67-111.87-112.26-117.99-119.98-130.02-134.98-146.78-148.34 (s, 
11C, C5H4/C6H3). 
2.3.12.4 Synthesis of complex [Cp-CH2-C6H5-(OCH3)2]2ScCl Bis-[(3,4-
dimethoxybenzyl)cyclopentadienyl]scandium-chloride.(CAM 8) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
3,4-dimethoxybenzyl-ciclopentedienile and 59 mg of ScCl3. We dissolved the 
ligand with 8 ml of anhydrous THF and moved the solution in the reaction 
flask. We solubilized the metal halide in 8 ml of THF-dry and we transferred 
into the dropping funnel. We immersed the flask in the thermostated bath at -
78 °C, and then slowly we added the metal in the solution containing the 
ligand. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid  




product in 40 ml of anhydrous dichloromethane, We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 37% 
1
H NMR (400 MHz, DMSO): 2.89 (d, 4H, CH2), 3.62 (d, 4H, CH2), 
3.72 (s, 12H, OCH3), 6.01 (s, 2H, C5H4), 6.13 (s, 2H, C5H4), 6.25 (s, 2H, 
C5H4), 6.41 (s, 2H, C5H4), 6.88 (m, 4H, C6H4), 7.15 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 55.01 (s, 4C, OCH3), 36.33 (s, 2C, 
CH2), 111.97-112.22-114.99-1120.42-122.13-132.67-137.24-148.94-149.19 
(s, 22C, C5H4/C6H3). 
 
2.3.13 Synthesis of neodymium cyclopentadienyl complexes 
 
2.3.13.1 Synthesis of complexes [C5H4–CH2–C6H4–OCH3]NdCl2. [(4-
methoxybenzyl)cyclopentadienyl]-neodymium-dichloride.(CAM 9) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
4-methoxybenzyl-ciclopentedienile and 195 mg of NdCl3. We dissolved the 
ligand with 6 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 24 ml of THF-dry and we 
transferred it to the reaction flask. We immersed the flask in the thermostated 
bath at -78 °C, and then slowly we added the ligand in the solution containing 
the metal halide. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 50 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we  




carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 49% 
1
H NMR (250 MHz. DMSO): 2.87 (d, 2H, CH2), (d, 2H, CH2), 3.71 (s, 
3H, OCH3), 5.99 (s, 1H, C5H4), 6.10 (s, 1H, C5H4), 6.23 (d, 1H, C5H4), 6.39 
(m, 1H, C5H4), 6.85 (m, 2H, C6H4), 7.10 (m, 2H, C6H4). 
13
C-NMR (300 MHz, DMSO): 53.89 (s, 1C, OCH3), 40.67 (s, 1C, 
CH2), 112.75-125.44-126.12-127.34-130.22-131.26-131.98-133.99-134.01-
145.45-156.89 (s, 11C, C5H4/C6H4). 
 
2.3.13.2 Synthesis of complex [Cp-CH2-C6H5-OCH3]2NdCl Bis-[(4-
methoxybenzyl)cyclopentadienyl]-neodymium-chloride.(CAM 10) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
4-methoxybenzyl-ciclopentedienile and 97 mg of NdCl3. We dissolved the 
ligand with 6 ml of anhydrous THF and moved the solution in the reaction 
flask. We solubilized the metal halide in 24 ml of THF-dry and we transferred 
into the dropping funnel. We immersed the flask in the thermostated bath at -
78 °C, and then slowly we added the metal in the solution containing the 
ligand. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane, We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 









H NMR (300 MHz, DMSO,): 2.86 (s, 4H, CH2), 3.68 (d, 4H, CH2), 
3.80 (s, 6H, OCH3), 6.14 (s, 2H, C5H4), 6.30 (s, 2H, C5H4), 6.41 (d, 2H, C5H4), 
6.85 (s, 2H, C5H4), 7.10 (m, 4H, C6H4), 7.12 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 53.30 (s, 2C, OCH3), 41.87 (s, 2C, 
CH2), 112.11-124.78-124.97-128.34-129.40-130.12-130.68-132.67-133.02-
144.56-155.15 (s, 22C, C5H4/C6H4). 
 
2.3.13.3 Synthesis of [C5H4–CH2–C6H3(OCH3)2]NdCl2 [(3,4-
dimethoxybenzyl)-cyclopentadienyl]-neodymium-dichloride. (CAM 11)  
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 
3,4-dimethoxybenzyl-ciclopentedienile and 169 mg of NdCl3. We dissolved 
the ligand in 5 ml of anhydrous THF and moved the solution into the dropping 
funnel. We solubilized the metal halide in 10 ml dry THF and transferred it to 
the reaction flask. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the ligand in the solution containing the metal 
halide. We left it on stirring overnight and climbing slowly to room 
temperature. We removed the solvent and we dissolved the resulting solid 
product in 40 ml of anhydrous dichloromethane. We filtered the mixture 
through celite to remove lithium chloride. We dried the complex and we 
carried it in dry box to recover and to weight it. The product was characterized 
by NMR analysis proton. 
Yield: 30% 
1
H-NMR (250 MHz, CDCl3): 2.87 (s, 2H, CH2), 3.70 (s, 6H, OCH3), 
6.01 (s, 1H, C5H4), 6.16 (s, 1H, C5H4), 6.28 (s, 1H, C5H4), 6.42 (s, 1H, C5H4), 
6.67-6.86 (m, 3H, C6H3). 
 





C-NMR (300 MHz, DMSO): 54.50 (s, 2C, OCH3), 35.77 (s, 1C, 
CH2), 110.12-111.34-113.27-117.89-121.67-130.55-134.67-146.22-147.37 (s, 
11C, C5H4/C6H3). 
 
2.3.13.4 Synthesis of complex [Cp-CH2-C6H5-(OCH3)2]2NdCl Bis-[(3,4-
dimethoxybenzyl)-cyclopentadienyl]-neodymium-chloride.(CAM 12)) 
 
We weighed in dry-box, in two separate balls, 150 mg of salt of lithium 3,4-
dimethoxybenzyl-ciclopentedienile and 75 mg of NdCl3. We dissolved the 
ligand with 6 ml of dry THF and moved the solution into the reaction flask. 
We solubilized the metal halide in 11 ml dry THF and transferred it to the 
dropping funnel. We immersed the flask in the thermostated bath at -78 °C, 
and then slowly we added the metal in the solution containing the ligands. We 
left it on stirring overnight and climbing slowly to room temperature. We 
removed the solvent and we dissolved the resulting solid product in 40 ml of 
anhydrous dichloromethane. We filtered the mixture through celite to remove 
lithium chloride. We dried the complex and we carried it in dry box to recover 
and to weight it. The product was characterized by NMR analysis proton. 
Yield: 55% 
1
H NMR (DMSO, 400 MHz): 2.87 (d, 4H, CH2), 3.60 (d, 4H, CH2), 
3.70 (s, 12H, OCH3), 5.98 (s, 2H, C5H4), 6.11 (s, 2H, C5H4), 6.23 (s, 2H, 
C5H4), 6.39 (s, 2H, C5H4), 6.86 (m, 4H, C6H4), 7.12 (m, 4H, C6H4). 
13
C-NMR (300 MHz, DMSO): 55.87 (s, 4C, OCH3), 36.79 (s, 2C, 
CH2), 112.30-112.89-113.21-120.02-122.95-132.67-137.87-149.54-150.01 (s, 
22C, C5H4/C6H3). 
 




2.3.14 MTT assay. 
 
We dissolved the compounds in a solution 100% concentrated of DMSO. 
From this we obtained the dilutions (5µm-10µm-20µm-50µm-100µm) in 
multiwell having plates 96 are deposited (plated) 2X10
4 
cells. After 24 hours 
are used the compounds that are the subject of study in contact with the cells 
to the pre-set concentrations, in order to determine the lethal dose 50, the dose 
to which we have the 50% inhibition of cell growth. After 48 hours of 
exposure to our compound, it is determined the effect of the growth inhibition 
by a colorimetric assay. The assay of MTT is a measurement of sensitivity of 
the cell proliferation based on the reduction of the tetrazolium salt, 3,[4,5-
dimethylthiazol-2-]-2,5-diphenyl-bromide-tetrazolium (MTT). Changes in 
proliferative activity of the cell caused by our compounds, can be quantified 
with the MTT. The MTT is reduced to a insoluble formazan coloring, by 
mitochondrial enzymes associated with metabolic activity. The reduction of 
MTT is due primarily to glycolytic activity all inside the cell associated with 
the presence of NADH and NADPH. 
  




2.4 Results and discussion 
 
2.4.1 Synthesis of cyclopentadienyl ligands 
 
The selected ciclopentadienyl ligands were yet able to stabilize the 
titanium cation by intramolecular or intermolecular coordination. In particular 
these compounds were substituted aromatic with methoxyl groups (inducers of 
lipophilicity). 
Ligands were synthesized from 6-phenyl-fulvene, 6-(p-
methoxyphenyl)-fulvene, 6-(3',4'-dimethoxyphenyl)fulvene, 6-(2',4'-
dimethoxyphenyl)fulvene and 6-(3',5'-dimethoxyphenyl)fulvene. Structures of 














Figure 2.5. Structures of synthesized pro-ligands 
6-phenyl-fulvene  6-(p-methoxyphenyl)-fulvene  
6-(3',4'-dimethoxyphenyl)fulvene  












Synthesis of cyclopentadienyl ligands was carried out in four steps in inert 
nitrogen atmosphere. (figure 2.6).  
 
Step I 
Cyclopentadiene was obtained by a retro diels-alder of 
dicyclopentadiene. The process exploited the different boiling point of the 
dimer and the monomer. Therefore, the dimer was dropped into a solution of 
boiling decalin (180°C). The high temperature broke the dimer and formed the 
vapors of the cyclopentadiene, which converge in the head of a Claisen of the 
distiller. Cyclopentadiene condensed into a collection tube cooled with ice. 
 
Step II 
The synthesis of pro-ligands fulvenes was carried out starting from 
suitable aromatic aldehyde.  
Step III 
Lithium salt of ligands was synthesized reacting an appropriate fulvene 
with LiBEt3H (Super Hydride), in dry diethyl ether. Reaction was a 
nucleophilic addition of a hydride to the double bond 5-6 of fulvene, using 
LiB(Et)3H as a donor of reducing equivalents. We used a slight excess than the 
stoichiometric value of super-hydride. The choice of the LiB(Et)3H as 
reducing agent derived from its high selectivity. In fact, the double bond 5-6 of 
fulvene had a high polarity due to the inductive effect of the methoxyl group 
bonded to benzene. By this increase of the polarity, the reducing agent 
attacked the double bond 5-6 and not the dienic component of fulvene. We 
bought the super-hydride as 1 molar solution of THF, therefore, before use, we 
dried it from the solvent. 
 














Figure 2.6. Synthetic schemes of ligands.  
A: 6-phenyl-fulvene: R1=R2=R3=R4=H; 6-(p-metoxyphenyl)-fulvene: R1=R2=R4=H; 
R3=OCH3; 6-(3',4'-dimetoxyphenyl)fulvene: R1=R4=H; R2=R3=OCH3; 6-(2',4'-
dimetoxyphenyl)fulvene: R2=R4=H; R1=R3=OCH3;6-(3',5'-dimetoxyphenyl)fulvene: 
R1=R3=H; R2=R4=OCH3. 
B: 6-phenyl-cyclopentadienyl lithium intermediate: R1=R2=R3=R4=H 
6-(p-metoxyphenyl)cyclopentadienyl lithium intermediate: R1=R2=R4=H; R3=OCH3; 6-
(3',4'-dimetoxyphenyl)cyclopentadienyl lithium intermediate: R1=R4=H; R2=R3=OCH3; 6-
(2',4'-dimetoxyphenyl)cyclopentadienyl lithium intermediate: R2=R4=H; R1=R3=OCH3 ; 6-
(3',5'-dimetoxyphenyl)cyclopentadienyl lithium intermediate : R1=R3=H; R2=R4=OCH3 
 
 
The interesting results obtained with several of the synthesized 
compounds convinced us to expand the library of these group III complexes, 
making additional changes to the substituents of the cyclopentadienyl ring.  
Specifically, to complete the project, we designed the synthesis of 
cyclopentadienyl ligands binded with a pyridine, a 2,2'-bipyridine or a 1,10-
phenanthroline suitably replaced, or substituted with other nitrogenated 


































In the first case, we thought that the 2,2'-bipyridine or 1,10-
phenanthroline linked to the cyclopentadienyl ring could chelate and 
coordinate strongly the metal cation, thereby increasing the stability and 
improving in the antitumor activity.
(26)
 
Carbazoles with suitable functionalizations showed a significant 
cytotoxic activity on several cancer cell lines, therefore, in the second case, 
these groups, in association with the cyclopentadienyl derivatives of titanium, 
could hopefully have a synergistic effect in the antitumoral activity.
(27)
 
The synthesis procedure followed were those reported in the literature 
for the ligands synthesized in previous years. The synthesis will be carried out 
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Figure 2.8. Synthetic schemes of reaction of cyclopentadiene with 4-methoxy-
pyridyncarboxaldehyde 
 
However, the reactions have not led to the synthesis of the designed 
pro-binders. The reactions between cyclopentadiene and carbazoles was 
disadvantaged due to steric hindrance of the carbazole and cyclopentadiene 
and the synthesis is not occurred. Instead, the reaction with 4-pyridin-


























characterised) because of its poor stability in time. Probably the cause must be 
sought in the high reactivity of pyridine. 
2.4.2 Synthesis of group III cyclopentadienyl metal complexes 
 
The ligand synthesized had a various number of methoxyl group on 
aromatic ring linked to cyclopentadiene. New scandium(III), yttrium(III) and 
neodymium(III) complexes, both in the form of monosubstituted products both 
of disubstituted, were synthesized to evaluate the influence of these lipophilic 
group on the biological activity of the compounds. Structures of synthesized 
compounds are shown in figure 2.9.  
The group III metals have significant differences in atomic radius and 
electronegativity. Moreover we tried to study the correlation between these 
two parameters and antitumor activity.  
Synthesis was carried out in a only one step of reaction, in nitrogen 
inert atmosphere. The lithium salt of ligands was reacted with the suitable 

















































Figure 2.10. Synthetic scheme of cyclopentadienyl complexes. 
6-phenyl-cyclopentadienyl lithium intermediate: R1=R2=R3=R4=H; 6-(p-
metoxyphenyl)cyclopentadienyl lithium intermediate: R1=R2=R4=H; R3=OCH3; 6-(3',4'-
dimetoxyphenyl)cyclopentadienyl lithium intermediate: R1=R4=H; R2=R3=OCH3; 6-(2',4'-
dimetoxyphenyl)cyclopentadienyl lithium intermediate: R2=R4=H; R1=R3=OCH3; 6-(3',5'-
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2.4.3 Biological results 
 
Complexes were tested on MDA.MB213, breast carcinome cell-lines, 
not expressing the estrogen receptor ERα (ER-negative) and DU145, prostatic 
carcinoma.  
All complexes were tested by anchorage-dipendent assay (MTT assay). 
The yellow tetrazolium salt 3-[4,5-dimethylthiazol- 2yl]-2,5-diphenyl-
tetrazolium bromide (MTT) is reduced by metabolically active cells, in part by 
the action of dehydrogenase enzymes, to generate reducing equivalents such as 
NADH and NADPH. The resultant intracellular purple formazan can be 
solubilized and quantitated by spectroscopic means. MTT Cell Proliferation 
Assay allows measurement of proliferation rate and conversely, when 
metabolic events lead to apoptosis or necrosis, the reduction in cell viability. 
All complexes were solved in DMSO, tested at various concentration. 
Cell viability was expressed as the percentage of proliferated cells compared 
to cells treated with the different compounds . The same cells were used as 
control. 
CAM-2 showed concentration-dependent cell growth inhibition 
activity. At higher concentrations the inhibition of growth is stronger (about 
100%), contrary to lower concentrations is lower (45%) The compound also 
showed an activity of DL50 at low concentrations (5µM). From the graphs we 
was be excluded that the activity of the compound can be added to that of the 
solvent. We can say finally that the compound object of our study shows a 










Figure 2.11. Evaluation of the inhibitory activity of CAM 2 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
 
CAM-3 showed concentration-dependent cell growth inhibition 
activity. At higher concentrations the inhibition of growth is stronger (95%),  
A 
B 




contrary to lower concentrations is lower (58%) The compound also shows an 
activity of DL50 at low concentrations (5-10 µM). From the graphs was be 
excluded that the activity of the compound can be added to that of the solvent. 
We can say finally that the compound object of our study shows a strong 




Figure 2.12. Evaluation of the inhibitory activity of CAM 3 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
A 
B 




CAM-4 showed concentration-dependent cell growth inhibition 
activity. At higher concentrations the inhibition of growth is stronger (88%), 
contrary to lower concentrations is lower (14%) The compound also shows an 
activity of DL50 at low concentrations (20 µM). From the graphs was be 
excluded that the activity of the compound can be added to that of the solvent. 
We can say finally that the compound object of our study shows a strong 
activity inhibition of cell growth, tumor refers to antiblastic activities. 
 
 
Figure 2.13. Evaluation of the inhibitory activity of CAM 4 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
A 
B 




CAM-6 showed concentration-dependent cell growth inhibition activity. At 
higher concentrations the inhibition of growth is only of 50%, at lower 
concentrations is almost nothing (0/40%) The compound also shows an 
activity of DL50 at low concentrations (50/100 µM). From the graphs was be 
excluded that the activity of the compound can be added to that of the solvent. 
 
 
Figure 2.14. Evaluation of the inhibitory activity of CAM 6 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
A 
B 




CAM-7 showed concentration-dependent cell growth inhibition 
activity. At higher concentrations the inhibition of growth is stronger (80%), 
but at lower concentrations is very low (0/40%) The compound also shows an 
activity of DL50 at low concentrations (50/100 µM). From the graphs was be 
excluded that the activity of the compound can be added to that of the solvent. 
 
 
Figure 2.15. Evaluation of the inhibitory activity of CAM 7 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
A 
B 




CAM-9 showed cell growth inhibition activity concentration-
dependent. At higher concentrations the inhibition of growth is stronger (95-
90%), contrary to lower concentrations is lower (12-32%) The compound also 
showed an activity of DL50 at low concentrations (10/5 µM). In this case the 
solvent was involved in the toxic activity on the cell line. 
 
 
Figure 2.16. Evaluation of the inhibitory activity of CAM 9 on cell-growth of cell-
lines DU145 (A) and MDA.MB231 (B), determined by MTT assay. 
A 
B 




CAM-2, CAM-3 and CAM-4 lead a methoxyl group in the para 
position to the cyclopentadienyl ring. Instead, the aromatic ring of CAM-6 and 
CAM-7 leads two methoxyl group at the position 3 and 4. The first ones 
showed an antiproliferative activity better than the second compounds of the 
series. The biological activity of CAM-9 confirm the previous data. Indeed it 
has only one methoxyl group in position 4 of the aromatic rings and showed a 
good cell growth inhibitory activity at high concentration. Unfortunately for 
this experiment cannot be excluded the interference of the solvent in 
compound’s activity. 
By the assessment of the biological activity of the synthesized 
molecules, our compounds have a considerable effectiveness in the inhibition 
of the two considered solid tumors that depends on the chemical structure of 
the same. These compounds, therefore, represent a new class of molecules 
organo-metallic equipped with antiproliferative activity. Experiments 
performed on cell cultures of mammary tumors triple negative (MDA.MB213 
) and prostate cancers (DU145), establish that the inhibition of cell growth, 
obtained with some of the new synthesized molecules, can be referred to 
antiblastic activities, at concentrations employees with a lethal dose 50 (LD50) 
at low concentrations (5 µM) 
The good results obtained with the cell lines described above, have 
pushed us to test the molecules also on cell line B16F10 of melanoma. 
All complexes were solved in DMSO, tested at various concentration. 
Cell viability was expressed as the percentage of proliferated cells compared 










Figure 2.17. Evaluation of the inhibitory activity of  CAM 2 (A) and CAM 3 (B) on 













Figure 2.18. Evaluation of the inhibitory activity of CAM 6 (A) and CAM 7(B) on 
B16F10 (melanoma cell line) viability, determined by MTT assay. 
 
Preliminary data confirmed the results of the previous experiments, as 








bearing two methoxyl groups in position 3 and 4 showed a profile of growth 
inhibition was poor. 
 
2.4.4  Evaluation of drug-membrane interaction 
 
The partition coefficient of CAM-2 and CAM-7 were determined by 
UV-Vis spectrophotometry using liposomes as cell membrane mimetic 
models.  
The elimination of the light scattered by lipid vesicles is crucial in the 
aim to determine the partition coefficient of drugs. Therefore, in the present 
work the elimination of LUVs interference on the absorption spectra of the 
anticancer agents was obtained by subtracting each reference spectrum from 
the correspondent sample one and Equation (1) was used to calculate Kp of 
CAM-2 and CAM-7 from the data of the corrected absorption spectra.  Kp 
values were 1700 and 1200 for CAM 2 and CAM 7 respectively. 
The experimental results indicate that both the anticancer agents 
exhibit a significant membrane partition.  
 
  






We have synthesized and characterized several ligands and group III 
metal complexes linked with cyclopentadienil ligands. 
Complexes were tested on DU145 (prostatic carcinoma cell line), 
MDA.MB231 (breast carcinoma cell line, not expressing the estrogen receptor 
ERα) and B16F10 (melanoma cell line) to evaluate their cytotoxic potential 
activity. 
As indicated by our results, the presence of a coordinating group, such 
as phenyl or ether one, is important to stabilize the active species and generate 
a cytotoxic complex.  
CAM-2, CAM-3 and CAM-4 showed significant anti-proliferative 
effects. These three molecules which have a methoxyl group in para to the 
benzene ring, show the best biological activity and have been included in a 
patent application. 
Further study are needed to understand the exact mechanism through 
which these compounds exercise their action. 
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3 Chapter III 
 


















3.2.1 Carbene  
 
The carbene is a chemical species metastable with the general formula 





Figure 3.1. Chemical structure of carbene. 
It is widely used in organic chemistry and organometallic because of its 
reactivity. The properties of the carbon unsaturated bivalent atom depend on 
the nature and by the steric hindrance of the substituents R and R'. 
Geuther and Hermann, in 1855, were the first scientists to assume the 
existence of that chemical species. They affirmed that by alkaline hydrolysis 
of the chloroform could form this product. 
(1)
 At that time the existence of the 
radicals was not yet known and it was only 3 years after that Gomberg 
obtained by reaction of the triphenylchloromethane with metallic zinc in 
benzene, shown in figure 3.2, the first free radical that characterized by means 
of elemental analysis and chemical reactivity. 
(2) 
Cl
Zn +   1/2 ZnCl2
 
Figure 3.2. The reaction which led to the formation of the first free radical. 





From that moment onwards the scientific community welcomed its 
discovery and further contributions were made by Staudinger and Kupfer 
which revealed the existence of carbenic intermediates studying the formation 
of derivatives of the methylene and of the diazomethane. 
In the fifties the study on these new species was intensified and the growing 
interest toward the reactions, where were involved the carbenes, brought, a 
few years later, to the synthesis of derivatives of tropone by a reaction wherein 















Figure 3.3. The synthesis of derivatives of tropone by insertion of a methylene 
intermediate to substituted benzenes. 
 
Subsequent studies identified the geometry and properties of carbenes. 




Figure3.4. Electronic states of carbenes: singlet (A), triplet (B). 
A B 





In the singlet state, one of the three hybrid orbital sp
2 
of the carbon 
atom carries a pair of electrons of non-bond that justifies the nucleophilic 
function, while the not occupied orbital p is responsible of the electrophilic 
characteristics. In the state of triplet, instead the carbon atom has two orbital p 
containing unpaired electrons and orbital 2 hybridized sp.
(4)
 
In 1915, Chugaev, together with his collaborators, reported a study 
which showed the production of platinum complexes to bridge according to 
the reaction shown in figure 3.5: 
 










Figure 3.5. The synthesis of the salt of Chugaev. 
 
This one was the first true synthesis of metal-carbene complex, but 
unfortunately there were still the spectroscopic techniques necessary to 
confirm this theory.  
Only in 1964, while the carbenes were in vogue in organic chemistry, 
Fischer scored and marked in an unequivocal way the first tungsten-based 






















Figure 3.6. The synthesis of the first complex metal-carbene 
 
The carbene metal complexes have general formula LnMXm where M 
is the metal that constitutes the center of reaction, L is the carbene, the ligand 
capable of influencing the electronic properties of the metal and, consequently, 
the possible catalytic activity of the complex and X is a not carbenic ligand. In 
most cases it can be a halide, a carboxylate or an alkoxide anion. A particular 
type of carbenichave is LnM formula. In this complexes the metal is located in 
an oxidation state of zero.  
The complexes between a carbene and a transition metal can be of 3 
types as schematically shown in figure 3.7. 
 
Figure 3.7. Types of complex metal-carbene. 
 
In the complexes of Fischer it has the donation of the pair of electrons 
on the part of the binder to the metal and the donation of the pair of electrons 
of the metal to the binder which gives the complex a partial character of the 
double bond.  
 
 




In the complexes of Schrock, the interaction C-M occurs between the unpaired 
electrons of the metal and the electrons of the carbon carbenic atom in the state 
of triplet with the formation of a bond that approximates the covalent bond. 
In the complexes Arduengo-Wanzlick the orbital of the carbon 
carbonic atom is involved in aromatic conjugation and retrodonation is 




The complexes Arduengo-Wanzlick, also known as carbenic N-
heterocyclic complex, were used primarily for their catalytic activity but in 
recent years their use has also been extended in scope pharmacological. 
 
3.2.2 N-heterocyclic (NHC). Carbenes 
 





Figure 3.8. Chemical structure of a N-heterocyclic carbene. 
 
The first stable N-heterocyclic (NHC) carbene was obtained from 
Arduengo
(5)









Figure 3.9. Synthesis of Arduengo of first carbene N-heterocyclic stable 
 
The imidazolium salt taken up, N,N-diadamantil imidazolium chloride 
was reacted with NaH and a catalytic amount of DMSO in a THF solution. 
The reaction by-products, such as H2 and NaCl, was easily separated from the 
THF solution colourless. Arduengo obtained crystals. The X-ray analysis of 
these crystals showed unequivocally the structure of carbene 9 which falls 
between the imidozolin-2-unsaturated ilydene that probably represents the 
largest group of heterocyclic carbenes stable. However the discovery of 
Arduengo was only the starting point because in the next 15 years other NHC 
variously substituted were isolated and many of made metal complexes were 
proved to have good catalytic activity. The imidazolium salt (as for example 
the precursor 8) can be prepared by two synthetic strategies: the nucleophilic 
substitution to 2 nitrogen atoms or a multicomponent reaction. Imidazole is 
initially deprotonated on nitrogen. Subsequently an alkyl halide and/or aryl 
radical attacks the electrophilic centre previously generated and eventually the 
replacement occurs to load of the second nitrogen atom with another 
equivalent of halide. Usually this method is limited to the introduction of 
substituents primary alkyl, while a symmetrical substitution of both the  
 




nitrogen atoms of the ring can be realized in a synthesis one-pot in the 


























Figure 3.10. Synthesis of imidazolium salts N,N-disubstituted symmetrical and 
asymmetrical. 
 
In the multicomponent reaction instead an amine, glyoxal and 
formaldehyde in the presence of a Bronsted acid reacts forming a salt of 




























Figure 3.11. Synthesis of a salt of imidazolium realized with a multicomponent 
reaction 
 
However the condensation product between the amine and the glyoxal 
can also be isolated before cyclization with formaldehyde which gives the 
possibility of synthesizing an NHC with bulky substituents on the nitrogen 
atoms. 




A salt of imidazolium asymmetrically N,N-disubstituted can be 
obtained by combining a multicomponent cyclization with a N-alkylation as 

























Figure 3.12. Combination of multicomponent reaction and a N-alkylation to 
synthesize a salt of imidazolium asymmetrically N,N-disubstituted. 
  




3.3 Aim of the project 
 
The researches on N-heterocyclic carbene groups (NHC) started with 
the synthesis of the first stable NHC by Arduengo: 1,3-bis(adamatil)-imidazol-
2-ylidene. The ease of synthesis of these molecules and the possibility of 
coordinating the transition metals with consequent formation of metal 
complexes NHC, justify broad use both in the catalytic field that biological.  
The objective of this project was to synthesize new silver, gold and 
copper complexes with binders NHC in order to test the potential 
pharmacological activity. The structures of these complexes were realized to 
evaluate the influence of increased lipophilicity on the pharmacological effect, 
as known from the literature.
(8)
 Indeed, the lipophilic cation delocalized can 
pass through biological membranes more quickly and concentrate mainly in 
the mitochondria of cancer cells. 
NHC-ligand lipophilicity can increase replacing the hydrogens in positions 4 
and 5 of the imidazole ring, or functionalizing the nitrogen atoms with 
lipophilic substituents.  
Objective of the work was the changes to the positions 4 and 5 of the 
imidazole ring. Both the iodine synthesized salts exhibit the same substituents 
at the nitrogen atoms or a cyclopentanol on the nitrogen atom 1 and a methyl 
on the nitrogen atom 3 while differ for the substituents in position 4 and 5. In 
particular the salt R3 binds two chlorine atoms, while R5 binds two phenyl 
groups. 
In the last part of our work, instead, starting from the imidazole, it is 
also evaluated the effect of a different substituent on one of the two nitrogen 
atoms on the pharmacological activity. It presents in position 1 a side chain 
containing a phenyl group and a hydroxyl group and in position 3 there is once 
again the methyl.  
 




Finally, antiproliferative activity of new synthetic complexes, in breast 
carcinoma cells was evaluated.  




3.4 Materials and methods 
 
3.4.1 General procedure 
 
All manipulations were carried out under oxygen and moisture-free 





All the solvents were thoroughly deoxygenated and dehydrated under 
argon by refluxing over suitable drying agents, while NMR deuterated 




All chemicals were obtained from Aldrich chemical Co. and used 
without further purification.  
 
3.4.4 Characterization techniques 
 
1




H COSY and 
13
C NMR spectra 
were recorded on Bruker Avance 250 Spectrometer operating at 250 MHz (
1
H) 
and 62,5 MHz (
13
C), on Bruker Avance 300 Spectrometer operating at 300 
MHz (
1
H) and 75 MHz (
13
C) and on a Bruker Avance 400 Spectrometer 
operating at 400 MHz (
1
H) and 100 MHz (
13
C). Chemical shifts referred to 
tetramethylsilane used as internal standard. 
 




Molecular weights were determined by ESI mass spectrometry. ESI-MS 
analysis in positive and negative ion mode, were made using a Finnigan LCQ 
ion trap instrument, manufactured by Thermo Finnigan (San Jose, CA, USA), 
equipped with the Excalibur software for processing the data acquired. The 
sample was dissolved in acetonitrile and injected directly into the electrospray 
source, using a syringe pump, which maintains constant flow at 5 µl /min. The 
temperature of the capillary was set at 220°C. 
 
3.4.5 Synthesis of NHC-ligands 
 
3.3.5.1 Synthesis of L20 salt N-methyl-N’-[(2-hydroxy-2-phenyl)ethyl]-
imidazole iodire 
 
We added 6 g of imidazole and 10.6 g of 1,2-epoxyethylbenxene in a 
100 ml two-necked reaction flask. Mixture was stirred for 48 hours at 60°C. 
After this time, we added 12,5 g of methyl iodide and 20 ml of dry acetonitrile 
and we refluxed it for 5 hours. We cooled the reaction mixture to room 
temperature and we removed the solvent in a rotavapor to obtain a crude 
reaction product as a yellow oil. This one was dissolved in acetone and 
recovered by cold precipitation (-20°C) as a white powder. 
Yield: 18,2% 
1
H-NMR (300 MHz, DMSO): 9.10 (s, 1H, NCHN), 7.71-7.70 (d, 2H, 
CH=CH), 7.43-7.31 (m, 5H, aromatic H), 5.96 (d, 1H, OH), 4.95 (m, 1H, 
OCH), 4.43 (dd, 1H, NCH2), 4.22 (m, 1H, NCH2), 3.88 (s, 3H, NCH3). 
13
C-NMR (400 MHz, DMSO): 141.1 (NCHN), 136.9-128.3-127.7-
125.9 (aromatic C),123.0 (CH=CH), 70.5 (OCH), 55.6 (NCH2), 35.8 (NHC3). 
 
 




3.3.5.2 Synthesis of R3 salt N-methyl-N’-[2-hydroxycyclopentan]-4,5-
dichloroimidazole iodire 
 
We added 3 g of 4,5-dichloroimidazole and 3.70 g of 1,2-
epoxycyclopentane in a 50 ml two-necked reaction flask. Mixture was stirred 
for 48 hours at 60°C. After this time, we added 6,2 g of methyl iodide and 20 
ml of dry acetonitrile and we refluxed it for 24 hours. We cooled the reaction 
mixture to room temperature and we removed the solvent in a rotavapor to 
obtain a crude reaction product as a powdery yellow solid. This one was 




H-NMR (250 MHz, CD2Cl2): 9.59 (s, 1H, NCHN), 5.47 (d, 1H, OH), 
4.45 (m, 1H, CHO), 4.27 (m, 1H, CHN), 3.82 (s, 3H, HCH3). 
13
C-NMR (300 MHz, DMSO): 135,3 (NCHN), 119.3-118.5 (C=C), 
75.9 (OCH), 66.6 (NCH), 35.2 (NHC3), 31.3-28.5-19.6 (CH2CH2CH2). 








We added 2 g of 4,5-diphenylimidazole, 0,35 g of K and 8 ml di DMF in a 25 
ml two-necked reaction flask. Mixture was stirred until the complete 
dissolution of the potassium at room temperature. The resulting yellow 
solution was stirred for 17 hours at 100 °C after the addition of 0,84 g of 1,2-
epoxycyclopentane. After this time, we recovered the reaction product in three 
times. We added, firstly, a volume of water 10 times greater than the volume  




of DMF. We filtered the mixture, recovering a yellow solution and a white 
precipitated, than dissolved in chloroform. We washed the chloroform solution 
firstly with a HCl 5N solution and then with water. We dried the resulting 
solution with magnesium sulphate and we removed the solvent by a rotavapor. 
We recovered the reaction product, for the first time, after cold-precipitations 
(-20°C) firstly from acetone and then from ethyl acetate.  
The yellow solution was extracted with chloroform and dried with 
magnesium sulphate. In this way, we recovered a white solid, washed firstly 
with acetone and then with ethyl acetate to obtain the second fraction of 
reaction product. 
Finally we neutralized the acid solution with a solution of NaOH at 
40%. We extracted the neutral solution just obtained with chloroform, washed 
it with water and dried it with magnesium sulphate. We filtered and removed 




H-NMR (250 MHz, CD2Cl2): 7.55 (s, 1H, NCHN), 7.35-7.12 (m, 
10H, aromatic H), 4.35 (m, 1H, CHO), 3.89 (m, 1H, CHN), 1.48-2.02 (m, 6H, 
CH2CH2CH2). 
13
C-NMR (250 MHz, CD2Cl2): 137.2 (NCHN), 134.7-133.7-131.7-
130.6-129.9-128.9-128.8-128.3 (aromatic C), 126.9-126.5 (C=C), 77.8 (CHO), 
63.2 (CHN), 31-4-31.3-19.5 (CH2CH2CH2). 
ESI-MS (CH3CN, m/z): 305.6 Dalton referred to [C20H21N2O]
+
; 221.6 




We added 0,55 g of the product of the previous step, 2,58 g methyl iodide and 
15 ml of acetonitrile in a 25 ml two-necked reaction flask. Mixture was stirred 
for 3,5 hours at 82 °C. We cooled the reaction mixture to room temperature  




and we removed the solvent in a rotavapor to obtain a crude reaction product. 
This one was dissolved in acetone and recovered by cold precipitation (-20°C). 
Yield: 52,6% 
1
H-NMR (300 MHz, CD2Cl2): 9.98 (s, 1H, NCHN), 7.45-7.38 (m, 
10H, aromatic H), 4,91 (m, 1H, CHO), 4.35 (d, 1H, OH), 4,25 (d, 1H, CHN), 
3.88 (s, 3H, NCH3), 1,87-1,84 (m, 6H, CH2CH2CH2). 
13
C-NMR (250 MHz, DMSO): 134,7 (NCHN),132-131.3-131.2-130.6-
130-129-128.9 (aromatic C) 125.3- 125.1 (C=C), 76.9 (CHO), 64.9 (NCH), 
34.8 (NHC3), 31.4-30.6-19.4 (CH2CH2CH2). 
ESI-MS (CH3CN, m/z): 319,7 Dalton referred to [C21H23I2N2O]
+
, 




3.4.6 Synthesis of silver(I)-NHC complexes 
 
3.3.6.1 Synthesis of AgR3 N-methyl-N’-[2-hydroxyciclopentan]-4,5-
dichloroimidazol-2-ilydene silver(I) iodire  
 
We added 2 g of R3 salt, 30 ml di dry CH2Cl2 and molecular sieves in a 
50 ml two-necked reaction flask. Mixture was stirred until the complete 
dissolution of the salt at room temperature. The resulting solution was refluxed 
sheltered from light for 1,5 hours after the addition of 1,92 g of silver oxide. 
After this time, we filtered the solution in nitrogen atmosphere, and we 
removed the solvent in vacuum trap by trap. The resulting product was washed 
with dry hexane and recovered as a black powder. 
Yield: 25,2% 
1
H-NMR (ppm CD2Cl2) 4.86 (m, 1H, CHO), 4.68 (m, 1H, CHN), 3.83 
(s, 3H, NCH3), 2.26- 1.74 (m, 6H, CH2CH2CH2)  





C-NMR (300 MHz CD2Cl2) 183.0 (NCHN), 118.6-117.3 (C=C), 
76.7 (CHO), 68.5 (CHN), 39.0 (NCH3), 33.0-29.8-20.7 (CH2CH2CH2). 




3.3.6.2 Synthesis of AgR5 N-methyl-N’-[2-hydroxyciclopentan]-4,5-
diphenylimidazol-2-ilydene silver(I) iodire  
 
We added 0,15 g of R5 salt, 25 ml di dry CH2Cl2 and molecular sieves 
in a 50 ml two-necked reaction flask. The resulting suspension was stirred and 
refluxed, sheltered from light, for 2 hours after the addition of 0,53 g of silver 
oxide. After this time, we filtered the solution in nitrogen atmosphere, and we 
removed the solvent in vacuum trap by trap. The resulting product was washed 
with dry hexane and recovered as a beige powder. 
Yield: 25% 
1
H-NMR (250 MHz, CD2Cl2): 7.34-7.25 (m, 10H, aromatic H), 5,12 
(m, 1H, CHO), 4.26 (d, 1H, CHN), 3.78 (s, 3H, NCH3), 1.49-2.24 (m, 6H, 
CH2CH2CH2). 
13
C-NMR (400 MHz, DMSO) 176.5-175.7 (NCHN), 133.3-132.9-
132.8-132-131.6-130.9-129.4-129.2-128.9-128.8 (aromatic C), 127.7- 127.6-
127.5 (CH=CH), 78.5-78.4 (CHO), 65.1-63.2 (CHN), 38.3-38.2 (NCH3), 32.8-
31.06- 20.3 (CH2CH2CH2). 
ESI-MS (CH3CN, m/z): 765 Dalton referred to [C42H44AgN4O2]
+
 with 
loss of a water molecule and addition of a potassium ion; pick at 319 referred 
to the fragmentation of monomer complexes that lost a phenyl group and 
acquired a potassium ion. 
 
 




3.3.6.3 Synthesis of AgL20 N-methyl-N’-[2-hydroxy-phenyl)ethyl]-imidazole-
2-ilydene silver(I) iodire  
 
We added 0,5 g of L20 salt, 25 ml di dry CH2Cl2 and molecular sieves 
in a 100 ml two-necked reaction flask. 1,92 g of silver oxide were added to the 
resulting solution. This one was stirred and refluxed for 1,5 hours sheltered 
from light. After this time, we filtered the solution in nitrogen atmosphere, and 
we removed the solvent in vacuum trap by trap. The resulting product was 
washed with dry hexane and recovered as a beige powder. 
Yield: 43,6% 
1
H-NMR (300 MHz, CD2Cl2): 7.32-7.27 (m, 5H, aromatic H), 6.80-
6.68 (d, 2H, CH=CH) 5,15 (m, 1H, CHO), 4.43 (m, 2H, CH2N), 3.81 (s, 3H, 
NCH3). 
13
C-NMR (300 MHz CDCl3) 141.3 (NCHN), 129.1-128.7-128-126.5 
(aromatic C), 122.5-121.3 (CH=CH), 73.3(CHO), 59.1 (CH2N), 38.9 (NCH3). 




3.4.7 Synthesis of gold(I)-NHC complexes 
 
3.3.7.1 Synthesis of AuR3 N-methyl-N’-[2-hydroxyciclopentan]-4,5-
dichloroimidazol-2-ilydene gold(I) iodire  
 
We added 0,5 g of AgR3 complexes and 15 ml di dry CH2Cl2 in a 25 
ml two-necked reaction flask. Mixture was stirred until the complete 
dissolution of the complex at room temperature. The resulting solution was 
refluxed overnight, sheltered from light and at room temperature after the 
addition of 0,16 g of chloro(dimethylsufide)of gold (I). After this time, we 
filtered the solution in nitrogen atmosphere, and we removed the solvent in  




vacuum trap by trap. The resulting product was washed with dry hexane and 
recovered as a brown powder. 
Yield: 77,2% 
1
H-NMR (250 MHz, CD2Cl2): 5.08 (m, 1H, CHO), 4.90 (d, 1H, CHN), 
3.88 (s, 3H, NCH3), 2.29- 1.73 (m, 6H, CH2CH2CH2)  
13
C-NMR (250 MHz, CD2Cl2) 183.6 (NCHN), 119-117.8 (C=C), 76.8 
(CHO), 71.3 (CHN), 38 (NCH3), 32.9-29.6-21 (CH2CH2CH2). 




3.3.7.2 Synthesis of AuR5 N-methyl-N’-[2-hydroxyciclopentan]-4,5-
diphenylimidazol-2-ilydene gold (I) iodire  
 
We added 0,093 g of AgR5 complexes, 25 ml di dry CH2Cl2 in a 50 ml two-
necked reaction flask. Mixture was stirred until the complete dissolution of the 
complex at room temperature The resulting solution was stirred and refluxed, 
sheltered from light, for 5 hours after the addition of 0,025 g of 
chloro(dimethylsulfide) of gold (I). After this time, we filtered the solution in 
nitrogen atmosphere, and we removed the solvent in vacuum trap by trap. The 




H-NMR (400 MHz, CD2Cl2) 7.41-7.16 (m, aromatic H), 5.43-5.19 
(m, 1H, CHO); 4.65 (d, 1H, OH); 4.30-4.18(m, 1H, CHN); 3.78 (s, 3H, 
NCH3), 2.63-1.53 (m, 6H, CH2CH2CH2). 
13
C-NMR (400 MHz, DMSO) 166.3 (NCHN), 132.8-131.4-130.6-
129.3 (aromatic C ), 128.6-127.3 (C=C), 77.8 (CHO), 65.5 (CHO), 37.9 
(NCH3), 32.7-32.3-20.4 (CH2CH2CH2). 




3.3.7.3 Synthesis of AuL20 N-methyl-N’-[2-hydroxy-phenyl)ethyl]-imidazole-
2-ilydene gold (I) iodire  
 
We added 0,123 g of AgL20 salt, 20 ml di dry CH2Cl2 and molecular 
sieves in a 100 ml two-necked reaction flask. 1,92 g of silver oxide were 
added to the resulting solution. Mixture was stirred until the complete 
dissolution of the complex at room temperature The resulting solution was 
stirred and refluxed, sheltered from light, for 4 hours after the addition of 
0,083 g of chloro(dimethylsulfide) of gold (I). After this time, we filtered the 
solution in nitrogen atmosphere, and we removed the solvent in vacuum trap 
by trap. The resulting product was washed with dry hexane and recovered as 
an orange powder. 
Yield: 17,2% 
1
H-NMR (300 MHz, CD2Cl2): 7.39-7.38 (m, 5H, aromatic H), 7.02-
6.90 (d, 2H, CH=CH) 5,20 (m, 1H, CHO), 4.47 (m, 2H, CH2N), 3.80 (s, 3H, 
NCH3). 
13
C-NMR (400 MHz, CDCl3) 171.8 (NCHN), 140.9-129.5-128.9-
126,4 (aromatic C), 122.8-121.7 (CH=CH), 74.5(CHO), 58.6 (CH2N), 38.7 
(NCH3). 




3.4.8 Synthesis of copper(I)-NHC complexes 
 
3.2.9.1 Synthesis of CuR3 N-methyl-N’-[2-hydroxyciclopentan]-4,5-








We added 0,5 g of R3 salt and 25 ml di dry THF in a 100 ml two-
necked reaction flask. Mixture was stirred for 1 hours at room temperature. 
We prepared copper chloride suspension in acetonitrile and then we added it to 
the R3 solution. The resulting suspension was refluxed for 24 hours. After this 
time, we filtered the solution in nitrogen atmosphere, and we removed the 
solvent in vacuum trap by trap. The resulting brown solid was dissolved in dry 




H-NMR (250 MHz, CD2Cl2): 4.70 (m, 1H, OH ), 4.58 (m, 1H, CHO), 
4.12 (m, 1H, CHN), 3.87 (s, 3H, NCH3), 2.18-1.71 (m, 6H, CH2CH2CH2). 
13
C-NMR (300 MHz, DMSO): 149.0 (NCHN), 106.0-105.4 (C=C), 
73.4(CHO), 61.3 (CHN), 32.0 (NCH3), 31.6-19.4-13.6 (CH2CH2CH2). 
 
3.3.8.2 Synthesis of CuR5 N-methyl-N’-[2-hydroxyciclopentan]-4,5-
diphenylimidazol-2-ilydene copper(I) iodire  
 
We added 0,1 g of R5 salt, 0,041 g di lithio-bis(trimethyl)silamide and 
15 ml di dry THF in a 100 ml two-necked reaction flask. Mixture was stirred 
for 1 hour. We prepared copper chloride suspension in acetonitrile and then we 
added it to the R3 solution. The resulting suspension was refluxed overnight. 
After this time, we filtered the solution in nitrogen atmosphere, and we 
removed the solvent in vacuum trap by trap. The resulting product was 
dissolved in dry CH2Cl2 and stirred for 4 hours at 4 °C to precipitate R5 ligand 
and to recover the copper complex. 
Yield: 30% 
 





H-NMR (250 MHz, CD2Cl2): 7.25-7.19 (m, 10 H, aromatic H ), 5.15 
(m, 1H, CHO), 3.79 (m, 1H, CHN), 3.66 (s, 3H, NCH3), 2.25-1.73 (m, 6H, 
CH2CH2CH2). 
13
C-NMR (400 MHz, CD2Cl2): 174.2 (NCHN), 133.6-133.3-133.0-
131.7-131.6-131.3-131.0-130.8 (aromatic C) 128.6-129.1 (C=C), 80.5(CHO), 
68.3 (CHN), 38.6 (NCH3), 34.3-33.5-21.1 (CH2CH2CH2). 
  




3.4.9 Biological procedures 
 
3.3.9.1 Cell cultures 
 
  Cell lines used in these studies were: 
 MCF-7: Human breast carcinoma cell line that expresses the estrogen 
receptor ERα (ER-positive. The cell line was maintained in culture in 
Dulbecco's Modified Eagle's Medium/Nutrient mixture F-12 HAM 
(DMEM/F12), with the addition of 5% Newborn calf serum (NCS) and 
100 units/ml penicillin-streptomicina. 
 MDA.MB-231: Human breast carcinoma cell line not expressing the 
estrogen receptor (ER-negative). The cell line was maintained in 
culture in Dulbecco's Modified Eagle's Medium/ Nutrient mixture F-12 
HAM (DMEM/F12), with the addition of 5% Fetal Bovine Serum 
(FBS), 1% L-glutamine and 100 units/ml penicillin-streptomycin. 
 MCF-10A: breast glandular healthy epithelium cell line. The cell line 
was maintained in culture in Dulbecco's Modified Eagle's Medium/ 
Nurient mixture F-12 HAM (DMEM/F12), with the addition of 5% 
horse serum (HS), growth factor of epidermis (EGF) 0,02 μg/ml 
hydrocortisone 0,5 μg/ml, cholera toxin 0,1 μg/ml insulin, 10 μg/ml 
and penicillin/streptomycin 100 units/ml. 
Cells were maintained in culture at a temperature of 37°C in humidified 
atmosphere with 5% CO2, inside an incubator for cells. Each experiment was 
performed using plates multi-well. Cells, after trypsinization, were plated in a 
defined quantity. The treatments were carried out in free of red phenol 
DMEM/F12 with 2% NCS. 






The trypsinization was the technique used to remove cells adhered to 
the bottom of the plate of maintenance. We aspirated the culture medium from 
the plate and we washed the plate for three times with phosphate buffered 
saline (PBS) to remove the serum residues. Then we added tripsin, a 
protolithic enzyme able to remove cells from the substrate. The plate was left a 
few minutes in the incubator until the cells begin to detach. The cells were 
then suspended again in medium containing serum to neutralize the trypsin, 
counted and used appropriately.  
 
3.3.9.3 Cell counting  
 
Cell count is based on the exclusion of the dye Trypan Blue from 
viable cells, unlike the dead cells, possessing a cytoplasmic membrane 
integrates, does not allow its penetration in the cytoplasm. A share of the cell 
suspension obtained following trypsinization, suitably diluted in the colorant, 
and this dilution was loaded in a Burker chamber, to allow the count of the 
cells under a microscope. The number of cells/ml was calculated with the 
equation: 
Average number of cells counted/square x dilution factor x factor of 




3.3.9.4 Cell proliferation assays: MTT assay  
 
 




The MTT-assay is a cell proliferation assay, which makes it possible to 
assess the viability of the cells in culture. It is based on the ability of viable 
cells to reduce the MTT (bromide of 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium) in corresponding insoluble formazan reaction, catalyzed 
by mitochondrial reductase. This assay of cell viability was performed on cells 
(3x10
4
/well) plated in multiwell x24, following treatment with the compounds 
under examination. The culture medium contained in each well were added 
100 μl of MTT solution 2mg/ml and the cells were allowed to incubate for 2 
hours at 37°C. The metabolically active cells converted the yellow MTT into 
insoluble purple formazan. The medium was aspirated from each well, and the 
formazan crystals present inside the cells were solubilized with 500 μl of 
dimethyl sulfoxide (DMSO). The intensity of the coloration of the solution of 
formazan is directly proportional to the number of viable cells, and measured 
in a spectrophotometer at a wavelength of 570 nm. 
 
3.3.9.5 Cell proliferation assays: Soft Agar Assay  
 
Soft agar assay allows to evaluate the ability of the cells to form 
colonies in the absence of adhesion to the substrate (proliferation anchorage-
independent) and its possible modulation following treatment with the 
compounds under examination. The cells (15000/well) were plated in 2 ml of 
Medium 5% cs-FBS to 0.35% Agarose (top layer) on the basis of medium to 
0.7% agarose (bottom layer) on the bottom of the plate by twelve wells. After 
a day after sowing, was added to the cells, the treatment medium, and this was 
renewed every three days. After 2 weeks, 100 μl of MTT were added to each 
well, leaving the plate in an incubator at 37°C for 4 hours and subsequently  
 




over-night at 4°C. The colonies of size greater than 50 μm were then counted 
under the microscope.  
 
3.3.9.6 Preparation of total protein extracts  
 
Cells were plated in multiwell x6 in complete culture medium and 
treated with the compounds under examination. At the end of the treatment 
period the medium was transferred into centrifuge tubes and centrifuged at 
1500 rpm for 5 minutes. The cells present in the treatment means are then 
recovered as pellets. Cell lysis was carried out by adding to each well of the 
plate 100 μl of lysis buffer (HEPES 50 mM pH 7.5, NaCl 150 mM, MgCl2 1.5 
mM, 1 mM EGTA, glycerol 10%, Triton-X-100 1%, PMS-F 1 mM, Aprotinin 
0.2 mM Naortovanadato, 0.2 mM). The buffer of lysis, uniformly distributed 
on the plate, disrupted the cell membranes allowing the recovery of the whole 
protein cell content. The activity of the protease was inhibited by 
fenilmetansulfonil-fluoride (PMSF), aprotinin and Na-orthovanadate, protease 
inhibitors added to the buffer of lysis at the moment of use. After 5 minutes, 
the content of each well was used to resuspend the pellet previously obtained, 
and the suspension was then transferred to an eppendorf and kept on ice for 30 
minutes, vortexing every 5 minutes. The content of each eppendorf was then 
centrifuged at 14000 rpm for 10 minutes at 4°C. The pellets was constituted by 
the cellular membranes, while the supernatant, the protein extract soluble, was 








3.3.9.7 Determination of the protein concentration  
 
The determination of the protein concentration of the cell extract was 
carried out by the spectrophotometric method of Bradford. This dosage was 
more advantageous than commonly used assays. It was characterized by a high 
sensitivity, a reduced presence of interference the dye used has an absorption 
relatively stable, requires only one reagent and has a reaction time of 5 
minutes. The protein assay was based on the observation that the maximum of 
the absorption of an acidic solution of Coomassie Brilliant Blue G-250 moved 
from 465 nm to 595 nm when the dye, of an acidic nature, bindings to the 
basic residues of proteins. The dosage is executed building, first, a calibration 
straight line. We prepared different cuvettes with 1 ml of reagent of Bradford 
(diluted 1:5) added with known amounts of bovine serum albumin (BSA). The 
mixture was stirred and reacted for 5 minutes. Finally we read the absorbance 
at the spectrophotometer at a 595 nm. wavelength. After we prepared the 
calibration straight line, we proceeded to the analysis of unidentified samples, 
preparing various cuvettes, each with 1 ml of the diluted dye and 10 μl sample 
incognito, suitably diluted. The absorbance values at 595 nm of the protein 
samples were reported on the calibration line, obtaining in this way the 
respective concentration values. 
 
3.3.9.8 Electrophoresis of proteins in denaturing conditions (SDS-PAGE)  
 
25 μg of proteins from each sample, were separated by SDS-
polyacrylamide gel electrophoresis. The percentage of acrylamide in the gel 
was chosen as a function of the molecular weight of the proteins that we 
wanted to study. The polyacrylamide gel was composed of two parts: the  




stacking gel and the resolving gel. The first, placed in the upper part, 
represented the portion of the gel in which we created the wells of loading. 
Furthermore it allowed to "pack" all the loaded material so that it arrives 
uniformly on the front of the race. The second is the portion of the gel where 
the true and proper electrophoretic run that allows to separate the sample of 
interest according to its dimensions. Stacking Gel and resolving gels had same 
composition, but a different concentration of acrylamide, as reported in table 
3.1. 
 
Table 3.1 The composition of the stacking gel and the resolving gel 
 Stacking gel 10% 12% 15% 
H20 6,4 ml 4,9 ml 4,4 ml 3,43 ml 
A.A./BIS A.A. 
(30/0.2) 
1 ml 2,5 ml 3 ml 3,75 ml 
TRIS/HCl 1,876 
M* 
2,5 ml 2,5 ml 2,5 ml 2,5 ml 
SDS 10% 0,1 ml 0,1 ml 0,1 ml 0,1 ml 
APS 10 0,2 ml 0,2 ml 0,2 ml 0,2 ml 
TEMED 0,02 ml 0,02 ml 0,02 ml 0,02 ml 
 
* TRIS/HCl at pH 6,8 for stacking gel, at pH 8,8 for resolving gel. 
 
Before of electrophoretic separation, the samples were added to the 
Laemmli buffer (4% SDS, 20% glycerol, β-mercaptoethanol 10% 
bromophenol blue 0.004%, Tris-HCl 0.125%). Then the samples were brought 
to the same final volume by addition of the same buffer used for the extraction  




of the proteins. Proteins contained in each sample were subjected to a 
treatment of thermal denaturation, at 100°C for 5 minutes. Simultaneously to 
the samples, we loaded in a well of the gel, a marker of molecular weights 
known (Precision Plus Protein™ to Blue Standards, Bio-Rad), essential for the 
identification of the protein of interest. The electrophoretic run was carried out 
in a vertical apparatus for electrophoresis in the presence of a buffer of stroke 
(Tris 25 mM glycine, 1.4% SDS, 0.1%, pH 8.3), 100 Volt for about 120 
minutes. This operation allowed the separation of the proteins, negatively 




Proteins separated on a polyacrylamide gel are transferred by 
"electrotransfer" on a nitrocellulose membrane using a transfer apparatus in 
semi-dry (BIORAD). The gel and the membrane were immersed in the 
transfer buffer (20 mM Tris Glycine, 150mM, 0. 5% SDS and 20% methanol). 
We set up the transfer’s apparatus as a sandwich (sponge, nitrocellulose 
membrane, gel, two sponges). The transfer chamber was constituted by two 
parallel electrodes and the nitrocellulose membrane was placed between the 
gel and the anode. We applied to the transfer chamber an electrical current (25 
volts for 1 hour) perpendicular to the gel, and the proteins negatively charged 
will migrate from the gel toward the positive pole, being transferred on 
nitrocellulose membrane. The quality of the transfer can be verified through 
the reversible staining of the membrane with the Red Ponceau (solution at 1% 
of red Ponceau in 5% acetic acid). The membrane was decolorized by 
washings with TBST 1X (Tris buffer saline-Tween: Tween-20 0.1%, 10mM 
Tris/HCl and NaCl 100mM). 




3.3.9.10 Immunological detection 
 
The nitrocellulose membrane was subjected to stirring for 60 minutes 
at room temperature in blocking solution, formed by TBST 10X (Tris/HCl 
100mM, 1 M NaCl and tween-20 1%) with the addition of milk powder to 5%. 
The function of blocking solution was to block all hydrophobic sites present 
on the membrane, responsible otherwise of aspecific interactions with the 
antibody. Subsequently the membrane was washed three times for five 
minutes with TBST 1X and is incubated overnight at 4°C with a solution of 
TBST 10X 5 % BSA containing the primary antibody specific for the protein 
of interest. The excess of antibody was subsequently removed by three washes 
in TBST 1X. The antigen-antibody complexes were detected after incubation 
for a hour at room temperature with a secondary antibody specific (in solution 
TBST 10X with 5% powdered milk), able to recognize the constant portion of 
the IgG molecule used as primary antibody. The secondary antibody is 
conjugated to horseradish peroxidase, an enzyme capable of catalysing, in 
basic conditions, the oxidation of a substrate luminescent chemo, Enhanced 
Chemiluminescence Substrate (ECL), in a product able to impress a 
photographic plate. 
Primary antibodies used: 
 antibody anti-p21, rabbit IgG (Santa Cruz Biotechnology), dilution 
1:500; 
 antibody anti-p53, mouse IgG (Santa Cruz Biotecnology), dilution 
1:500; 
 Anti-PARP, rabbit IgG (Santa Cruz Biotecnology), dilution 1:500; 
 




 Anti-β-actin, mouse IgG (Santa Cruz Biotecnology), dilution 1:20000. 
 Anti-GAPDH, rabbit IgG (Santa Cruz Biotecnology), dilution 1:10000. 
Secondary antibodies used: 
 Antibody biotinylated goat anti-rabbit IgG (Santa Cruz 
Biotechnology), dilution 1:7000; 
 Antibody biotinylated goat anti-mouse IgG (Thermo Scientific), 
dilution 1:2000. 
 
3.3.9.11 Stripping of the nitrocellulose membrane 
 
After we have detected a certain protein on a nitrocellulose membrane 
of a Western blotting, we can reuse the same membrane for the analysis of 
another protein. Before we carried out a new analysis, we had to remove the 
antibodies bound to the membrane by a process called stripping. The 
membrane was washed for two times of 15 minutes with stripping buffer 
(glycine solution 0.2 M at pH 2.6), and then washed two times for 10 minutes 
with TBST 1X. The membrane was then stirred for 60 minutes at room 
temperature in blocking solution, and re-incubated with a new primary 
antibody. 
 
3.3.9.12 DNA Extraction 
 
The cells were plated on 100 mm plates. At the end of the treatment, 
the medium present in the plates was transferred into centrifuge tubes and  




centrifuged at 2500 rpm for 5 minutes. The cells present in the treatment 
means were then recovered as pellets. The cells, adhering on the bottom of the 
plate, were detached using trypsin, then neutralized by the addition of medium 
enriched of serum. The cell suspension was transferred into tubes happy the 
pellet of centrifugal first, and the suspension was subjected again to 
centrifugation for 5 minutes at 2500 rpm. To the obtained pellet, represented 
by the cells, were added 100 μl of lysis buffer (Tris/HCl 50μM, EDTA 20nM, 
NP-40 1%), and this was allowed to act overnight at -80°C. SDS and Rnase-A 
were added to respectively denature the proteins and the RNA. Lysates were 
incubated at 56°C for 2 hours. In this conditions, Rnase-A enzyme could act 
and, at the same time, inhibit the activity of Dnase, possibly present in the 
sample. enzyme proteinase-K was subsequently added to degrade the proteins, 
and the samples were incubated for 2 hours at 37°C. 500 μl of cold absolute 
ethanol and 65μL of sodium acetate 3M were then added to each sample, to 
precipitate the DNA. After incubation at -80°C, overnight, we centrifuged the 
samples for 20 minutes at 12000 rpm at 4°C. The supernatant was removed 
and the pellet, represented by the DNA precipitate was washed with cold 
ethanol at 75% to solubilize the salts precipitated together with the DNA. 
After centrifugation at 12,000 rpm for 20 minutes at 4°C, the supernatant and 
the pellet were removed, and the DNA was resuspended in 50 μl of TE-buffer 
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
 
3.3.9.13 DNA electrophoresis on agarose gel 
 
The agarose gel electrophoresis was a technique that allows to booth DNA 
molecules according to their size, exploiting their different speed of migration 
through the agarose gel, subjected to an electric field. The agarose gel was  




prepared at a concentration of 2% in TBE buffer (Tris-borate-EDTA) added 
with ethidium bromide, an intercalating agent that makes visible the DNA by 
fluorescence emission due to exposure to UV lamp. On agarose gel was loaded 
a marker, consisting of a mixture of DNA fragments having known molecular 
weight, and the different samples mixed with a loading buffer, containing 
thickening agents and dyes to facilitate loading of the samples and to monitor 
the progress of the electrophoretic run. 
  




3.5 Results and Discussion 
 
3.5.1 Synthesis of NHC ligands 
 
3.4.1.1 Synthesis of L20 salt. 
 
Synthesis of L20 salt N-methyl-N’-[(2-hydroxy-2-phenyl)ethyl]-
imidazole iodire was carried out in inert nitrogen atmosphere as shown in 
figure 3.13. Imidazole was reacted with 1,2-epoxyethylbenzene. Mixture was 
stirred for 24 h at 60°C to obtain the monoalkylated product after the opening 
of epoxy-ring. In this way was synthesized the monoalkylating product by the 
opening of the epoxy ring. The was added the second alkylating agent (CH3I) 
and acetonitrile and the mixture was refluxed for 3,5 h.  This second reaction 
step, with which the alkylation of the second nitrogen atom, ended with 
cooling to room temperature the mixture, removal of the solvent under 
vacuum (in a rotavapor) and recovery as a precipitate, cold acetone, in racemic 






















3.4.1.2 Synthesis of R3 salt.  
 
Synthesis of R3 salt N-methyl-N’-[2-hydroxycyclopentan]-4,5-
dichloroimydazole iodire was carried out in two steps in nitrogen atmosphere, 
as showed in figure 3.14. 
4,5-dichloroimydazole was reacted with 1,2-epoxycyclopentane. The 
mixture of reaction was stirred for 48 h at 60°C. In this way the epoxy ring 















Figure 3.14. Synthetic schemes of R3 salt. 
 
Then the second alkylating agent (CH3I) and CH3CN were added; the 
mixture was refluxed for 24 h. this second step of reaction, in which alkylation 
of second nitrogen atom was carried out, stopped with cooling to room 
temperature of mixture, removing of solvent (by rotavapor) and cold-
precipitation from acetone as racemic mixture of R3 salt. 





C-NMR) and by Mass Spectrometry 
 
3.4.1.3 Synthesis of R5 salt 
 
Synthesis of R5 salt N-methyl-N’-[2-hydroxycyclopentan]-4,5-
diphenylimydazole iodire was carried out in two steps in nitrogen atmosphere. 
In the first step, shown in figure 3.15, the amine nitrogen was deprotonated by  




potassium and the monoalkylated product was synthesized by the opening of 
the epoxy ring. The trans opening of the epoxy ring generated a molecule with 













Figure 3.15 Synthetic schemes of R5salt. 
 
Potassium was dissolved in a suspension of 4,5-diphenylimidazole in 
dimethylformamide (DMF) and then epoxide was added. Mixture was stirring 
for 17 h at 100 °C to alkylate one of the nitrogen atoms. For the work up, a 
quantity of water ten times greater than DMF was added and a white solid 
precipitated. The mixture was filtered, giving a yellow solution and a 
precipitate. This one was solved in chloroform. The solution was firstly 
washed with HCl 5N and then with water. The product was recovered as a 
white solid by cold-precipitation from ethyl acetate. Product was also 
recovered by yellow solution by extraction with chloroform. Then it was 
revovered by cold-precipitation from ethyl acetate. 
The second step of reaction, shown in figure monoalkylated product 
(obtained in first step) was reacted with iodomethane (CH3I) in acetonitrile 
(CH3CN). Mixture was stirred and refluxed for 3,5 h in inert nitrogen 
atmosphere. The product was recovered by cold-precipitation from acetone (-
20°C). Monoalkylated product (obtained in first step) was reacted with 
iodomethane (CH3I) in acetonitrile (CH3CN). Mixture was stirred and refluxed  
 




for 3,5 h in inert nitrogen atmosphere. The product was recovered by cold-
precipitation from acetone (-20°C). 
 
3.5.2 Synthesis of Ag-NHC complexes. 
 
Synthesis of Ag-NHC complexes AgR3 N-methyl-N’-[2-
hydroxycyclopentan]-4,5-dichloroimidazol-2-ylidene-iodire of silver (I), AgR5 
N-methyl-N’-[hydroxycyclopentan]-4,5-diphenylimidazol-2-ylidene-iodire of 
silver (I) and AgL20 N-methyl-N’-[(2-hydroxyphenyl)ethyl)]-imidazol-2-
ylidene-iodire of silver (I) was carried out as shown in figure 3.16 in inert 

















AgL20 R= -H R1=
OH
 
Figure 3.16. Synthetic schemes of Ag-NHC complexes. 
 




The salt (R3, R5, L20) was reacted with silver oxide (Ag2O) in 
dichloromethane (CH2Cl2) with molecular sieves. Reaction was refluxed and 
sheltered from light. In these conditions the silver oxide also acted as a base 
(tore the proton of carbon 2). In situ was generated the N-heterocyclic carbene 
that reacted with the metal creating the Ag-NHC complex. The water, formed 
as by-product, was subtracted from the molecular sieves, shifting the 
equilibrium of the reaction toward the right. The complexes Ag-R3, Ag-R5 
and Ag-L20 were obtained as a racemic mixture. 




C-NMR. The structure 
of the complexes was also confirmed by mass spectra. For Ag-R3 a peak at 
577.3 Dalton, attributable to the molecular ion [C18H24AgCl4N4O2]+, 
confirmed the structure. Ag-R5 mass-spectrum showed a peak at 765 Dalton, 
attributable to [C42H44AgN4O2]+ that loses a water molecule and buy a 
potassium ion, and a peak at 319.7 Dalton, attributable to a fragmentation in 
which the complex in the form of a monomer loses a phenyl and buy a 
potassium ion. For Ag-L20 was reported a peak 513 Dalton attributable to 
[C24H29AgN4O2]+. These mass values confirmed the literature datas., Mono-
NHC Ag (I) complexes in solution seems to be in equilibrium with the dimeric 















Figure 3.17. Structures of mono Ag-NHC complxes in solution.  
 




3.5.3 Synthesis of Au(I)-NHC complexes. 
 
Synthesis of Au-NHC complexes  AuR3 N-methyl-N’- [2-
hydroxycyclopentan]-4,5-dichloroimidazol-2-ylidene-iodire of gold (I), AuR5 
N-methyl-N’-[2-hydroxycyclopentan]-4,5-diphenylimidazol-2-ylidene-iodire of 
gold (I) and AuL20 N-methyl-N’-[(2-hydroxy-2phenyl)ethyl]-imidazol-2-
ylidene-iodire of gold (I) were carried out as shown in figure 3.18 in an inert 
atmosphere of nitrogen. These complexes were obtained by transmetallation 
from the corresponding complex of silver-NHC. Ag-NHC was reacted with 
chloro(dimethylsulfide) of gold (I) (CH3)2AuSCl, in dichloromethane 
(CH2Cl2). Reaction was carried out at room temperature, sheltered from light. 
In these conditions it was realized the transmetalation reaction wherein the 
atom of silver is replaced by an atom of gold  that bound to the carbenic 




















Figure 3.18. Synthetic schemes of Au-NHC complexes. 




3.5.4 Syntesis of Cu(I)-NHC complexes. 
 
Synthesis of Cu-NHCcomplexes CuR3 N-methyl-N’-
[2hydroxycyclopentan]-4,5-dichloroimidazol-2-ylidene-iodire of copper(I) e 
CuR5 N-methyl-N’-[2-hydroxycyclopentan]-4,5-diphenylimidazol-2-ylidene-
iodire of  copper(I). 
Synthesis was carried out as shown in figure 3.19 in nitrogen inert 
atmosphere. The salt (R3 or R5) was stirred with Lithium 
bis(trimethyl)sililamide in tetrahydrofuran (THF), until the complete 
dissolution of the salt. After 1 h, a suspension of copper chloride (CuCl) in 
acetonitrile was added in the mixture. Reaction refluxed overnight to 
synthesize a racemic mixture of Cu-NHC complexes. Copper complexes were 
unstable because of the rapid oxidation of the copper I to copper II in the 
presence of the oxygen atmospheric. Because of their insolubility, Cu-NHC 




















Figure 3.19. Synthetic schemes of Cu-NHC complexes  
 




3.5.5 Biological results 
 
AuR3 e AuL20 e AgL20 was tested on MCF-7 (breast carcinome cell-
line, expressing the estrogen receptor ERα, ER-positive), MDA-MB-231 
(breast carcinome cell-line, not expressing the estrogen receptor ERα, ER-
negative), MCF-10A (healthy glandular breast epithelium cell line). 
Antiproliferative activity of AuR3 was evaluated by cell proliferation 
assay anchorage-dependent (MTT-assay) on MCF-7. The complex was diluted 
in DMSO and tested at different concentrations (0.10μm, 1μm, 10μm and 25 
μm and 50 μm). Results are reported in the graph of figure 3.20. 
 
            
 
Figure 3.20. Effect induced by the treatment with the complex of AuR3 at different 





























AuR3 (μM)    -                  +               +                 +                 +                  + 
DMSO           +                  -               -                   -                  -                   -  




AuR3 showed a good inhibitory effect on the proliferation of this cell 
line. Was then evaluated the activity on MDA-MB-231 in the same conditions 
as the previous test and the results are shown in figure 3.12.  
 
Figure 3.21. Effects induced by the treatment with AuR3 on cellular proliferation 
anchorage-dependent of the tumor cell line MDA-MB-231. 
 
Also in this case the complex showed proliferative activity comparable 
to that observed with the previous cell line but at a concentration of 50 μM 
was more active on MCF-7. 
Finally, to exclude a possible toxicity of healthy cells,AuR3 was tested 
on MCF-10A, using the same experimental conditions of the previous 
experiments. As we can bee from the graph of figure 3.22, it can be noted a 




























AuR3 (μM)       -               +               +             +               +              + 
DMSO              +                -               -              -                -               -  





Figure 3.22. Effects induced by the treatment with AuR3 on proliferation anchorage 
dependent cell line MCF-10A. 
 
The antiproliferative activity of AgL20 and AuL20 was evaluated by 
cell proliferation assay anchorage-dependent (MTT-assay) on MCF-7. The 
complexes were diluted in DMSO and tested at different concentrations 
(10nm, 100nm, 1μm, 5μm and 10 μm). The antiproliferative effect was 
evaluated after a treatment period of three days. The absorbance values, read at 
590 nm, were related to that bed for a negative control represented by cells 

































AuR3 (μM)      -          +           +        +         +          + 
DMSO             +          -             -         -         -           -  





Figure 3.23. Effect induced by the treatment with the complex AuL20 and AgL20 at 
different concentration on cell proliferation anchorage-dependent of the tumor cell 
line MCF-7. 
 
We observed an inhibitory effect on the proliferation of this cell line, 
dose-dependent and a marked antiproliferative effect already at low 
concentrations. Between the two complexes tested, the gold one demonstrated, 
at equal concentration, greater antiproliferative than AgL20.  
From the results obtained, IC50 (concentration of the compound 
capable of inhibiting cellular proliferation of 50 % relative to the control) was 
calculated as the average of 5 experiments ± standard deviation. IC50 values 
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To confirm the antiproliferative activity observed with MTT-assay, 
was conducted a cell proliferation assay anchorage-independent (Soft Agar 
Assay) on the same cell line mammary MCF-7. The proliferation of the cells 
in the absence of a solid support mimics better conditions for the proliferation 
of tumor cells in the body, with respect to the proliferating in mono-layer, 
studied by the previous experiment of MTT assay. The ability of the cells of 
the line MCF-7 to form colonies, suspended in medium semi-solid, was 
evaluated after treatment of the cells with the two complexes, at 
concentrations 1 μm and 10 μM. The results of these experiments are reported 
in figure 3.24 and are expressed as the number of colonies of sizes greater than 
50 μm, counted under the microscope. These experiments gave results in 
agreement with the MTT assay and confirmed the activity of the complexes; 












Figure 3.24. Effects induced by the treatment with AuL20 and AgL20, on cellular 
proliferation anchorage-independent, of tumor cell line MCF-7. 
 
In order to evaluate the specificity of the antiproliferative effect only 
on tumor cell lines and therefore to exclude a possible toxicity on healthy cells 
was conducted a test of cell viability by MTT assay, on cell line MCF-10A. 
Cells were treated for three days with the two complexes, at the same 
concentrations used in the preliminary studies on MCF-7 and results, 
compared to the control, were reported in the graph of figure 3.25 from which 











Figure 3.25. Effects induced by the treatment with AuL20 and AgL20 on the 
proliferation anchorage dependent cell line MCF-10A 
 
Highlighted the absence of toxic effects on healthy cells, we decided to 
investigate if the antiproliferative activity exerted by AuL20 on MCF-7 was 
connected to the mechanisms of regulation of the cell cycle. Therefore, we 
evaluated the expression of two proteins involved in the regulation of the cell 
cycle, p53 and p21. 
 p53 is able to induce cell growth arrest, apoptosis and cellular 
senescence but in normal cells p53 is usually inactive, bound to the protein 
MDM2 that inhibits and promotes its degradation. Only after the cellular 
damage, such as for example a DNA damage, p53 is activated and stimulates 
the transcription of many genes including that which encodes for the protein 
p21. This proteins binds the complex cyclin-Cdk2 and cyclin-Cdk4 and it 
inhibits the activity, regulating the cell cycle progression at the level of the 
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Cells were treated with AuL20 (at concentrations of 100nM, 1μM and 5μM) 
for 24 hours. After this period were lysed was extracted the entire protein 
content which was then loaded on polyacrylamide gel allows for the 
electrophoretic separation of proteins. The expression of p21 and p53 was 
evaluated by immunoblotting. β-actin was used as “loading control" to 
confirm the loading of the same amount of protein for each sample. Results 
are shown in figure 3.26. 
 
 
Figure 3.26. The effects of treatment with AuL20 on the levels of expression of 
protein p53 and p21 in line mammary tumor MCF-7. 
 
Results showed a marked modulation of the expression of p21 and p53, 
confirming the involvement of these proteins in the antiproliferative activity of 
the complex AuL20 and the block of the proliferation of cells treated between 
the G1 phase and the step S. 




AuL20 and AgL20 were tested on MDA.MB-231. Cells were treated 
for three days with the complexes, at concentrations of 10 nM, 100 nM, 1 μm, 
5 μm and 10 μm. Cell proliferation was evaluated by MTT assay. The results, 
compared to the control, are shown in the graph of figure 3.27. 
 
 
Figure 3.27. Effects induced by the treatment with AuL20 and AgL20 on cellular 
proliferation anchorage-dependent of the tumor cell line MDA-MB-231. 
 
The complex AgL20 did not show any antiproliferative activity against 
cell line MDA-MB-231. We assumed for AgL20 a mechanism of action 
closely related to the expression of ER. Instead, AuL20 showed an intense 
antiproliferative activity also in breast carcinoma cells ER-negative. With the 
results obtained we calculated the value of IC50 on this cell line as the average 
of 5 experiments ± standard deviation (3.43 ± 1 μM ). The marked 
antiproliferative activity of AuL20, also observed in the absence of estrogen 
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ER expression. However by comparing the IC50 values obtained in cell lines 
MCF-7 and MDA-MB-231, it can be inferred that the presence of the estrogen 
receptor is partly related to the activity of the complex AuL20. The highest 
value of IC50, obtained in the tumor cell line ER-negative, is in fact indicate a 
lower activity of the complex. 
The involvement of the estrogen receptor in the mechanism at the base 
of the antiproliferative action of the complex AuL20 was deepened by 
immunoblot experiments. Variation of expression of ERα was evaluated on 
MCF-7 after treatment of the cell line with the complex AuL20. The cells 
were treated for 46 hours at 100 nM, 1 μM and 5 μM concentrations. The 
results reported in figure 3.28, showed a marked negative modulation of the 
expression of the receptor. 
 
 
Figure 3.28. The effects of treatment with AuL20 on the level of expression of the 








The reduction of the expression of this receptor was responsible for 
less stimulation of proliferation in the cell line ER-positive. This phenomenon 
justified the difference between the values of IC50 highlighted by previous 
experiments. 
The latest experiments were focused on the study of the mechanism of 
cell death induced by complex AuL20. By immunoblot experiments we 
evaluated the presence of cleavage of the enzyme poly ADP-ribose 
polymerase (PARP), a phenomenon characteristic of the apoptotic process. 
The cleavage of PARP was highlighted after treatment of the cell line MCF-7 
for 24 hours with the complex Aul20, at the highest concentration tested 
(5μm), as shown in figure 3.29.  
 
Figure 3.29. Cleavage of the enzyme PARP in line mammary tumor MCF-7 after 
treatment with the complex AuL20. 
 
To confirm the apoptosis as the mechanism of cell death, it was 
decided to study a second key event in the apoptotic process, DNA 
fragmentation (DNA laddering). For this purpose the breast tumor cell line 
MCF-7 were treated for 24 hours at concentrations of 1 μM and 5 μM and, at  




the end of the treatment period, the extracted DNA was subjected to 
electrophoresis separation on agarose gel. The result, shown in figure 3.30, has 
not revealed the DNA fragmentation. 
 In order to confirm or exclude definitively the induction of the 
apoptotic process on the part of the complex AuL20, are currently in progress 
new experiments to assess whether the phenomenon of fragmentation can be 
highlighted by prolonging the time of treatment beyond 24 hours. 
 
 
Figure 3.30. DNA extracted from the line mammary tumor MCF-7 after treatment 
with AuL20. 
  






In this project various complexes NHC based on silver, copper and 
gold were synthesized with the purpose of evaluating the influence, that 
greater lipophilicity of the salt and the respective complexes NHC, could have 
on the pharmacological effect. The first two salts synthesized have the same 
substituents on the nitrogen atoms or a cyclopentanol on the nitrogen atom 1 
and a methyl on the nitrogen atom 3 while differ for the substituents in 
position 4 and 5 of the imidazole ring. In particular the salt R3 binds two 
chlorine atoms while R5 binds two phenyl groups. The L20 salt was 
synthesized from the imidazole and it has a methyl group on the one nitrogen 
atom and a side chain containing a phenyl group and a hydroxyl group on the 
other nitrogen atom; in this case it is tried to understand what the different 
substituent on the nitrogen atom could influence the pharmacological effect. 
With these salts were synthesized complexes of silver and gold and copper 
which were then tested for their pharmacological activity. 
The complex AgL20 was tested on MCF-7 by cell proliferation assay 
anchorage-dependent (MTT-assay) and showed a good activity, confirmed 
with the cell proliferation assay anchorage-independent (Soft Agar Assay), 
always performed on the same cell line mammary (MCF-7). To demonstrate 
the specificity of the antiproliferative effect only in relation to tumor cell, a 
MTT assay on MCF-10A was carried out. Finally, AgL20 was tested on 
MDA-MB-231 cellular line. In this case, it has shown no activity; therefore, 
we can assume a mechanism of action of AgL20 related to the expression of 
the estrogen receptor. 
The complexes AuR3 and AuL20, instead, were tested on the same 
three cell lines used for AgL20. Both AuR3 that AuL20 showed 
antiproliferative activity on MCF-7 and MDA-MB-231 and no activity on  




MCF-10A thus demonstrating the absence of toxicity on healthy cells and a 
selective antiproliferative action toward the tumor cells. 
Biological studies AuL20 were intensified and oriented toward the 
search of the mechanism responsible for the antiproliferative activity. The 
cells of the line MCF-7, treated conAuL20 showed a negative modulation of 
the expression of two important proteins involved in the regulation of cell 
proliferation process, p53 and p21. The results obtained allow us to affirm that 
the treatment with the complex AuL20 determines the cell cycle arrest at the 
checkpoint G1/S. For AuL20 were also calculated values of IC50 on MCF-7 
and MDA-MB-231. Whereas the highest value of IC50 obtained with the tumor 
cell line ER negative-it was possible to deduce that the presence of the 
estrogen receptor is related to the activity of the complex. Therefore, on the 
basis of the results obtained, the activity of AuL20, seems to be due to both 
mechanisms related to estrogen receptor that independent mechanisms from 
the ER expression. While the last two experiments were carried out to 
understand what was the mechanism of cell death induced by the complex of 
gold in examination. Results showed the presence of cleavage of the enzyme 
poly ADP-ribose polymerase (PARP), a phenomenon characteristic of the 
apoptotic process. For further confirmation, we investigated on the other 
phenomenon characteristic of apoptosis: the DNA fragmentation. After 24 
hours of treatment, however, we did not highlight this event. In conclusion, 
from the preliminary data currently available, it can be stated that the carbenic 
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